Live financial news intelligence

Track market-moving stories before they get noisy

Real-time pulse of financial headlines curated from 5 premium feeds.

Latest market signal English
Coverage 172,102 Raw stories ingested 22,883 rewritten in CS_CZ • 0 to rewrite (last 2 days).
Agents 7 waiting Pipeline agents
  • FMP Stock News Fetch every minute 28s ago
  • FMP Forex News Fetch every 5 min 28s ago
  • CoinGecko News Fetch every 5 min 2m ago
  • FIO Stock News Fetch every 10 min 1m ago
  • Patria Stock News Fetch every 10 min 1m ago
  • Editorial rewrite Rewrite every minute 28s ago
  • Asset sync Assets every 1 hour 20m ago

Latest coverage

Market News Feed

Scan headlines quickly, then expand any story for source context.

View
Clear
Details Date Content Source
2026-06-12 19:39 3mo ago
2026-05-13 15:31 4mo ago
Zimmer Biomet Holdings, Inc. (ZBH) Presents at Bank of America Global Healthcare Conference 2026 Transcript
ZBH Zimmer Biomet Holdings
FMP Stock News
Original source text
Zimmer Biomet Holdings, Inc. (ZBH) Presents at Bank of America Global Healthcare Conference 2026 Transcript
2026-06-12 19:39 3mo ago
2026-05-18 10:16 3mo ago
ABT vs. ZBH: Which Surgical Equipment Stock Is the Better Bet Now?
ZBH Zimmer Biomet Holdings
FMP Stock News
Original source text
Key Takeaways Abbott completed Exact Sciences acquisition, adding $3B 2026 sales and expanding diagnostics.Zimmer Biomet posts organic growth and EPS gains, driven by new products and efficiency programs.ZBH raised 2026 EPS outlook to $8.40-$8.55 and trades at a lower forward valuation vs. history. Abbott (ABT - Free Report) and Zimmer Biomet (ZBH - Free Report) are two well-established names in the surgical equipment market, which is projected to expand at a CAGR of 8.72% between 2026 and 2032. Abbott, a diversified healthcare giant, has a dedicated Structural Heart portfolio that offers transcatheter and surgical devices for the repair and replacement of heart valves. On the other hand, Zimmer Biomet is a renowned name in the musculoskeletal space, focused on orthopedic reconstructive, sports medicine, trauma and surgical products, alongside integrated digital and robotic technologies.

As of today, Abbott holds a market capitalization of $147.13 billion, significantly larger than Zimmer Biomet’s $16.19 billion valuation. Let’s take a look at both companies to determine which one presents the stronger investment case.

The Case for AbbottThe company recently completed the acquisition of Exact Sciences, a strategic move that adds a new high-growth business to its portfolio and expands its presence into one of the fastest-growing areas of diagnostics. The deal is expected to contribute roughly $3 billion of 2026 incremental sales and support Abbott's long-term sales growth rate. First-quarter 2026 adjusted earnings per share (EPS) of $1.15 came in line with its expectations despite earlier-than-planned financing costs tied to the acquisition.

Core Lab Diagnostic test sales continued to show solid demand trends across the United States, Europe and Latin America, but remained flat in China, where government procurement policies have affected pricing and volumes. A weaker-than-expected respiratory season also weighed on Rapid and Molecular Diagnostics results.

In Nutrition, lower sales volumes persisted across both pediatric and adult product portfolios in the U.S. and international markets. Abbott introduced strategic pricing actions in late 2025 to help accelerate volume growth, which are beginning to show encouraging early signs. The company is also prioritizing innovation, with several nutrition product launches planned over the coming months. 

Meanwhile, Abbott’s Established Pharmaceuticals (EPD) performance benefits from favorable long-term healthcare economic and demographic trends, supported by a broad product offering across five therapeutic areas. The biosimilars portfolio, which includes several market-leading oncology therapies, is a key growth pillar.

Within Medical Devices, the cardiovascular businesses delivered a strong performance in the quarter, supported by the Aveir leadless pacemakers, the Heart Assist Devices portfolio and the launch of two new pulsed field ablation (PFA) catheters. In Diabetes Care, continuous glucose monitoring sales reached $2 billion, although growth was affected by delayed international tender renewal and a difficult prior-year comparison related to shelf restocking dynamics.

Abbott projects full-year 2026 adjusted diluted EPS of $5.38-$5.58, which includes $0.20 of dilution from the Exact Sciences acquisition, and maintains its organic growth outlook of 6.5% to 7.5%.

Here's how estimates for Abbott’s 2026 and 2027 bottom line are trending over the past 60 days.

Image Source: Zacks Investment Research

The Case for Zimmer BiometThe company delivered a solid first-quarter 2026, with sales growing 2.9% on an organic constant currency basis and adjusted EPS rising 15.5% year over year. Healthy end markets and continued momentum from newly-launched products supported the performance. Over the past two years, Zimmer Biomet has addressed key gaps in its core portfolio through the rollout of its “Magnificent 7” platform, which includes products like the Persona OsseoTi Keel Tibia, Oxford Cementless Partial Knee, and the ROSA Robotic Solutions and navigation technologies.

Within the U.S. hip franchise, the company continues to gain traction with its “triple-play”, comprising Z1 (now representing nearly 40% of U.S. hip stents), the OrthoGrid AI-based hip navigation platform and the HAMMR surgical impactor. Internationally, Zimmer Biomet is seeing rapid adoption of its iodine-coated hip implant in Japan, its second-largest market. Its strategy of offering a comprehensive suite of technology solutions is paying dividends.

Meanwhile, the ongoing transition to a dedicated and specialized U.S. sales channel from independent distributors and sales representatives is already generating improved productivity in transitioned territories. The evolution of go-to-market models, particularly in emerging markets, is also performing in accordance with the company’s plan.

Outside its core, Zimmer Biomet has diversified its portfolio with M&A. Paragon 28’s first-quarter growth accelerated roughly 200 basis points sequentially and is trending back toward double-digit growth. Zimmer Biomet is also advancing toward the anticipated 2027 launch of the mBos, a fully autonomous AI-driven orthopedic robotic system acquired through Monogram Technologies.

Actions such as manufacturing footprint expansion into lower-cost geographies, lowering inventory on hand and an ongoing SKU rationalization program are expected to strengthen Zimmer Biomet’s margins and improve free cash flow conversion rates.

The company reiterated its 2026 organic constant currency revenue growth outlook of 1% to 3% and raised adjusted EPS expectations to the $8.40-$8.55 range.

Take a look at how estimates for the company’s 2026 and 2027 earnings are shaping up.

Image Source: Zacks Investment Research

ABT & ZBH: Price Performance and ValuationSo far this year, ABT shares have dropped 32.6%, lagging both ZBH’s 6.9% decline and the Medical sector’s 7.7% fall.

Image Source: Zacks Investment Research

Abbott is trading at a forward earnings multiple of 14.83, below its median of 22.94 over the last three years. ZBH’s forward earnings multiple sits at 9.67, also lower than its three-year median of 12.73.

Image Source: Zacks Investment Research

ConclusionZimmer Biomet’s latest quarterly performance was shaped by shifting U.S. and certain international go-to-market strategies, while its recent acquisitions are showing positive momentum. The company is also making strides in improving operating efficiency. Meanwhile, Abbott’s first-quarter performance displayed respiratory-testing volatility in Diagnostics, early effects of pricing actions in Nutrition, and strength in EPD and Medical Devices.The Exact Sciences acquisition expands its addressable diagnostics market but presents near-term dilution risk. Estimates for Abbott’s 2025 and 2026 earnings are also trending downward.

On a year-to-date basis, ZBH has shown a stronger performance than Abbott while also appearing relatively more attractive on valuation. Rising earnings projections for the company are highly promising. Existing ZBH holders may find it prudent to retain their position to enjoy long-term momentum.

ZBH carries a Zacks Rank #3 (Hold), while ABT has a Zacks Rank #4 (Sell).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
2026-06-12 19:39 3mo ago
2026-05-18 10:40 3mo ago
Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock
ZBH Zimmer Biomet Holdings
FMP Stock News
Original source text
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.

The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.

Zacks Premium also includes the Zacks Style Scores.

What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.

Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.

Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.

VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.

That's where the Style Scores come in.

You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.

Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.

Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Zimmer Biomet (ZBH - Free Report) Headquartered in Warsaw, IN, Zimmer Biomet Holdings, Inc. is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries.

ZBH is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.

It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 9.89; value investors should take notice.

Nine analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.04 to $8.46 per share. ZBH boasts an average earnings surprise of +4.9%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, ZBH should be on investors' short list.
2026-06-12 19:39 3mo ago
2026-05-22 16:30 3mo ago
Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2026
ZBH Zimmer Biomet Holdings
FMP Stock News
Original source text
Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the second quarter of 2026. The cash dividend of $0.24 per share is payable on or about July 31, 2026 to stockholders of record as of the close of business on June 25, 2026.

About Zimmer Biomet

Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.

With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation. 

For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X at www.x.com/zimmerbiomet.

Contacts:

Media

Investors 

Troy Kirkpatrick

David DeMartino

614-284-1926

646-531-6115

[email protected] 

[email protected]

Kirsten Fallon

Zach Weiner

781-779-5561

908-591-6955

[email protected] 

[email protected]

SOURCE Zimmer Biomet Holdings, Inc.

Also from this source
2026-06-12 19:39 3mo ago
2026-05-28 12:36 3mo ago
Zimmer (ZBH) Up 3.1% Since Last Earnings Report: Can It Continue?
ZBH Zimmer Biomet Holdings
FMP Stock News
Original source text
It has been about a month since the last earnings report for Zimmer Biomet (ZBH - Free Report) . Shares have added about 3.1% in that time frame, underperforming the S&P 500.

But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Zimmer due for a pullback? Well, first let's take a quick look at its latest earnings report in order to get a better handle on the recent drivers for Zimmer Biomet Holdings, Inc. before we dive into how investors and analysts have reacted as of late.

ZBH Q1 Earnings & Revenues Top EstimatesZimmer Biomet posted first-quarter 2026 adjusted earnings per share of $2.09, which beat the Zacks Consensus Estimate by 12.6%. The adjusted figure rose 15.5% year over year.

The quarter’s adjustments included certain amortization, restructuring and other cost reduction initiatives, inventory and manufacturing-related charges and European Union Medical Device Regulation-related charges, among others.

GAAP earnings per share were $1.22 compared with 91 cents in the year-ago period. 

RevenuesNet sales of $2.09 billion increased 9.3% (up 6.8% on a constant currency basis) year over year. The figure also surpassed the Zacks Consensus Estimate by 1.8%.

Revenues by GeographySales generated in the United States totaled $1.21 billion (up 8.6% year over year) for the quarter, while International sales grossed $877.4 million (up 10.3% year over year on a reported basis and 4.2% at CER).

Segmental AnalysisThe company currently reports under four product categories — Knees, Hips, S.E.T. (Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic) and Technology & Data, Bone Cement and Surgical.

Sales in the Knees unit improved 1.8% year over year at CER to $828.6 million. 

Hips’ sales grew 3.2% year over year at CER to $524.1 million. 

Revenues in the S.E.T. unit rose 17.4% year over year at CER to $562.2 million. 

Technology & Data, Bone Cement and Surgicalrevenues rose 11.7% to $171.8 million at CER in the first quarter. 

Margin PerformanceAdjusted gross margin, after excluding the impact of intangible asset amortization, was 72.4%, reflecting an expansion of 119 basis points (bps) year over year. Gross margin expanded despite a 4.8% rise in the cost of products sold.

Selling, general and administrative expenses rose 12% to $849.9 million. Research and development expenses declined 6.5% to $103.4 million. Adjusted operating margin expanded 104 bps to 26.7%.

Cash PositionZimmer Biomet exited the first quarter of 2026 with cash and cash equivalents of $424.2 million compared with $591.9 million at the end of the fourth quarter of 2025.

Cumulative net cash provided by operating activities at the end of the first quarter was $359.4 million compared with $382.8 million in the year-ago period.

2026 OutlookZimmer Biomet has updated its EPS guidance for 2026.

Revenue growth is expected to be in the band of 2.5-4.5%. The Zacks Consensus Estimate for revenues is pegged at $8.52 billion, implying 3.6% year-over-year growth. 

Adjusted earnings per share guidance for the full year is now expected to be in the range of $8.40-$8.55 (previously $8.30-$8.45). The Zacks Consensus Estimate for 2026 adjusted earnings per share is pegged at $8.37.

How Have Estimates Been Moving Since Then?It turns out, estimates review have trended downward during the past month.

VGM ScoresCurrently, Zimmer has a average Growth Score of C, a score with the same score on the momentum front. Charting a somewhat similar path, the stock was allocated a grade of B on the value side, putting it in the top 40% for this investment strategy.

Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, Zimmer has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
2026-06-12 19:39 3mo ago
2026-06-02 07:30 3mo ago
Zimmer Biomet to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
ZBH Zimmer Biomet Holdings
FMP Stock News
Original source text
Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8 with a fireside chat at 10:40 a.m. ET.

A live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the fireside chat.

About Zimmer Biomet
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.

With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation. 

For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X at www.x.com/zimmerbiomet.

SOURCE Zimmer Biomet Holdings, Inc.

Also from this source
2026-06-12 19:39 3mo ago
2026-06-08 17:08 3mo ago
Zimmer Biomet Holdings, Inc. (ZBH) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
ZBH Zimmer Biomet Holdings
FMP Stock News
Original source text
Zimmer Biomet Holdings, Inc. (ZBH) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
2026-06-12 19:38 3mo ago
2026-04-29 14:10 4mo ago
Concurrent Investment Advisors LLC Raises Holdings in McKesson Corporation $MCK
MCK McKesson
FMP Stock News
Original source text
Posted by Defense World Staff on Apr 29th, 2026

Concurrent Investment Advisors LLC grew its position in McKesson Corporation (NYSE:MCK – Free Report) by 62.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,158 shares of the company’s stock after buying an additional 1,219 shares during the quarter. Concurrent Investment Advisors LLC’s holdings in McKesson were worth $2,590,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in MCK. Generali Investments Management Co LLC increased its position in McKesson by 500.0% during the 4th quarter. Generali Investments Management Co LLC now owns 1,014 shares of the company’s stock valued at $832,000 after buying an additional 845 shares in the last quarter. Calamos Wealth Management LLC increased its position in McKesson by 3.1% during the 4th quarter. Calamos Wealth Management LLC now owns 5,551 shares of the company’s stock valued at $4,553,000 after buying an additional 167 shares in the last quarter. ProVise Management Group LLC increased its position in McKesson by 3.0% during the 4th quarter. ProVise Management Group LLC now owns 14,991 shares of the company’s stock valued at $12,297,000 after buying an additional 433 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in McKesson by 3.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 1,600 shares of the company’s stock valued at $1,314,000 after buying an additional 52 shares in the last quarter. Finally, Lebenthal Global Advisors LLC increased its position in McKesson by 99.2% during the 4th quarter. Lebenthal Global Advisors LLC now owns 741 shares of the company’s stock valued at $608,000 after buying an additional 369 shares in the last quarter. 85.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at McKesson In related news, CAO Napoleon B. Rutledge, Jr. sold 328 shares of the stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $955.00, for a total value of $313,240.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Leann B. Smith sold 190 shares of the stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $945.00, for a total value of $179,550.00. Following the completion of the sale, the executive vice president directly owned 2,989 shares of the company’s stock, valued at approximately $2,824,605. This represents a 5.98% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 3,592 shares of company stock worth $3,518,555. 0.08% of the stock is owned by insiders.

McKesson Trading Up 0.8% Shares of MCK stock opened at $834.55 on Wednesday. The company has a market capitalization of $102.22 billion, a P/E ratio of 24.00, a P/E/G ratio of 1.20 and a beta of 0.42. The business’s 50 day moving average is $899.76 and its two-hundred day moving average is $859.72. McKesson Corporation has a 12-month low of $637.00 and a 12-month high of $999.00.

McKesson (NYSE:MCK – Get Free Report) last released its earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share for the quarter, beating the consensus estimate of $9.19 by $0.15. The business had revenue of $106.16 billion for the quarter, compared to the consensus estimate of $105.98 billion. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The business’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same quarter last year, the business posted $8.03 earnings per share. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. On average, research analysts predict that McKesson Corporation will post 39.02 earnings per share for the current fiscal year.

McKesson Dividend Announcement The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 1st. Stockholders of record on Monday, June 1st will be given a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Monday, June 1st. McKesson’s dividend payout ratio (DPR) is 9.43%.

Wall Street Analysts Forecast Growth Several research analysts recently issued reports on the company. TD Cowen upped their target price on McKesson from $1,000.00 to $1,012.00 and gave the company a “buy” rating in a research report on Thursday, February 5th. Morgan Stanley reiterated an “overweight” rating and issued a $966.00 target price on shares of McKesson in a research report on Thursday, January 29th. Mizuho upped their target price on McKesson from $880.00 to $885.00 and gave the company a “neutral” rating in a research report on Thursday, February 5th. Leerink Partners reiterated an “outperform” rating and issued a $1,085.00 target price on shares of McKesson in a research report on Thursday, March 5th. Finally, Bank of America dropped their target price on McKesson from $1,040.00 to $1,000.00 and set a “buy” rating on the stock in a research report on Monday, April 6th. Fourteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $972.27.

Check Out Our Latest Stock Analysis on McKesson

McKesson Profile (Free Report)

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.

Recommended Stories Five stocks we like better than McKesson Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Corporation (NYSE:MCK – Free Report).

Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEConcurrent Investment Advisors LLC Buys 4,936 Shares of Cadence Design Systems, Inc. $CDNS

NEXT HEADLINE »Concurrent Investment Advisors LLC Takes Position in Nu Holdings Ltd. $NU
2026-06-12 19:38 3mo ago
2026-04-29 18:51 4mo ago
McKesson (MCK) Falls More Steeply Than Broader Market: What Investors Need to Know
MCK McKesson
FMP Stock News
Original source text
In the latest close session, McKesson (MCK - Free Report) was down 1.48% at $822.63. The stock trailed the S&P 500, which registered a daily loss of 0.04%. Elsewhere, the Dow saw a downswing of 0.57%, while the tech-heavy Nasdaq appreciated by 0.04%.

The stock of prescription drug distributor has fallen by 3.51% in the past month, lagging the Medical sector's loss of 0.72% and the S&P 500's gain of 12.24%.

The investment community will be paying close attention to the earnings performance of McKesson in its upcoming release. The company is slated to reveal its earnings on May 7, 2026. In that report, analysts expect McKesson to post earnings of $11.56 per share. This would mark year-over-year growth of 14.23%. In the meantime, our current consensus estimate forecasts the revenue to be $101.88 billion, indicating a 12.18% growth compared to the corresponding quarter of the prior year.

For the annual period, the Zacks Consensus Estimates anticipate earnings of $39.02 per share and a revenue of $409.05 billion, signifying shifts of +18.06% and +13.92%, respectively, from the last year.

Investors should also note any recent changes to analyst estimates for McKesson. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.

Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.45% higher. As of now, McKesson holds a Zacks Rank of #3 (Hold).

With respect to valuation, McKesson is currently being traded at a Forward P/E ratio of 18.87. This signifies a premium in comparison to the average Forward P/E of 15.78 for its industry.

Investors should also note that MCK has a PEG ratio of 1.2 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As the market closed yesterday, the Medical - Dental Supplies industry was having an average PEG ratio of 1.63.

The Medical - Dental Supplies industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 55, which puts it in the top 23% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
2026-06-12 19:38 3mo ago
2026-04-30 11:06 4mo ago
McKesson (MCK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
MCK McKesson
FMP Stock News
Original source text
McKesson (MCK - Free Report) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.

The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on May 7. On the other hand, if they miss, the stock may move lower.

While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.

Zacks Consensus EstimateThis prescription drug distributor is expected to post quarterly earnings of $11.56 per share in its upcoming report, which represents a year-over-year change of +14.2%.

Revenues are expected to be $101.92 billion, up 12.2% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 0.54% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for McKesson?For McKesson, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -0.07%.

On the other hand, the stock currently carries a Zacks Rank of #3.

So, this combination makes it difficult to conclusively predict that McKesson will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that McKesson would post earnings of $9.31 per share when it actually produced earnings of $9.34, delivering a surprise of +0.32%.

Over the last four quarters, the company has beaten consensus EPS estimates four times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

McKesson doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

An Industry Player's Expected ResultsAnother stock from the Zacks Medical - Dental Supplies industry, Staar Surgical (STAA - Free Report) , is soon expected to post earnings of $0.13 per share for the quarter ended March 2026. This estimate indicates a year-over-year change of +125%. Revenues for the quarter are expected to be $91.8 million, up 115.5% from the year-ago quarter.

The consensus EPS estimate for Staar Surgical has remained unchanged over the last 30 days. However, a lower Most Accurate Estimate has resulted in an Earnings ESP of -15.39%.

When combined with a Zacks Rank of #3 (Hold), this Earnings ESP makes it difficult to conclusively predict that Staar Surgical will beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates three times.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
2026-06-12 19:38 3mo ago
2026-05-04 10:16 4mo ago
Countdown to McKesson (MCK) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
MCK McKesson
FMP Stock News
Original source text
Wall Street analysts expect McKesson (MCK - Free Report) to post quarterly earnings of $11.56 per share in its upcoming report, which indicates a year-over-year increase of 14.2%. Revenues are expected to be $101.92 billion, up 12.2% from the year-ago quarter.

Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.5% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.

Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.

While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.

With that in mind, let's delve into the average projections of some McKesson metrics that are commonly tracked and projected by analysts on Wall Street.

Analysts forecast 'Revenue- North American Pharmaceutical' to reach $84.12 billion. The estimate indicates a change of +1.2% from the prior-year quarter.

The collective assessment of analysts points to an estimated 'Revenue- Medical-Surgical Solutions' of $2.94 billion. The estimate points to a change of +3% from the year-ago quarter.

Analysts' assessment points toward 'Revenue- Prescription Technology Solutions' reaching $1.47 billion. The estimate suggests a change of +9.8% year over year.

Based on the collective assessment of analysts, 'Adjusted Operating Profit- Medical-Surgical Solutions' should arrive at $284.53 million. The estimate is in contrast to the year-ago figure of $285.00 million.

The combined assessment of analysts suggests that 'Adjusted Operating Profit- North American Pharmaceutical' will likely reach $991.34 million. The estimate is in contrast to the year-ago figure of $1.05 billion.

Analysts predict that the 'Adjusted Operating Profit- Prescription Technology Solutions' will reach $310.20 million. The estimate compares to the year-ago value of $285.00 million.

View all Key Company Metrics for McKesson here>>>

Over the past month, McKesson shares have recorded returns of -8% versus the Zacks S&P 500 composite's +10% change. Based on its Zacks Rank #3 (Hold), MCK will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
2026-06-12 19:38 3mo ago
2026-05-07 14:35 4mo ago
Should You Buy, Sell, or Hold McKesson Before Q4 Earnings?
MCK McKesson
FMP Stock News
Original source text
MCK heads into Q4 earnings with strength in oncology, GLP-1 demand, and biopharma services, but softer medical-surgical trends may weigh.
2026-06-12 19:38 3mo ago
2026-05-07 16:10 4mo ago
McKesson Reports Fiscal 2026 Fourth Quarter and Full Year Results, Provides Fiscal 2027 Guidance, and Reaffirms Long-Term Financial Growth Targets
MCK McKesson
FMP Stock News
Original source text
-

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) has released its fiscal 2026 fourth quarter financial results. Results can be accessed on McKesson’s Investor Relations website at investor.mckesson.com/financials/quarterly-results.

As previously announced, the company will host a live webcast of the earnings conference call for investors today, Thursday, May 7, at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company’s earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at investor.mckesson.com/events-and-presentations.

About McKesson Corporation

McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Stories & Insights.

We routinely use our website, investor.mckesson.com, to post information that may be material to investors, such as business developments, earnings, and financial performance, as well as presentation materials and details for upcoming and past events.

More News From McKesson Corporation

Back to Newsroom
2026-06-12 19:38 3mo ago
2026-05-07 17:50 4mo ago
McKesson expects 2027 profit slightly above estimates on drug distribution strength
MCK McKesson
FMP Stock News
Original source text
CompaniesMay 7 (Reuters) - McKesson (MCK.N), opens new tab forecast 2027 profit slightly above Wall Street expectations after beating first-quarter profit estimates ​on Thursday, as the U.S. drug distributor ‌banks on strength in its oncology and specialty drug businesses.

McKesson and peers, including Cardinal Health (CAH.N), opens new tab and Cencora (COR.N), opens new tab, ​are capitalizing on surging demand for ​high-cost specialty drugs used to treat rheumatoid ⁠arthritis and cancer, helping generate strong margins.

Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.

On an ​adjusted basis, the company expects fiscal 2027 profit ​per share of $43.80 to $44.60, with the midpoint of $44.20 slightly above analysts' estimate of $44.10, according to data compiled by ​LSEG.

J.P. Morgan analysts described McKesson's fiscal 2027 ​guidance as 'better than feared', noting that despite softer U.S. ‌distribution ⁠trends at peers Cardinal Health and Cencora during the quarter, the outlook appears reasonable and consistent with the company's long-term growth expectations.

The Texas-based ​company reported ​fourth-quarter revenue ⁠of $96.3 billion, compared with expectations of $101.35 billion.

On an adjusted basis, the largest ​pharmaceutical distributor in the U.S. earned $11.69 ​per ⁠share for the quarter, beating analysts' estimates of $11.59.

McKesson's U.S. pharmaceutical unit, its largest segment by revenue, ⁠recorded ​sales of $79.1 billion, an increase ​of 3%, driven by higher volumes of specialty products.

Reporting by ​Padmanabhan Ananthan in Bengaluru; Editing by Jonathan Ananda

Our Standards: The Thomson Reuters Trust Principles., opens new tab
2026-06-12 19:38 3mo ago
2026-05-07 18:55 4mo ago
McKesson (MCK) Surpasses Q4 Earnings Estimates
MCK McKesson
FMP Stock News
Original source text
McKesson (MCK - Free Report) came out with quarterly earnings of $11.69 per share, beating the Zacks Consensus Estimate of $11.56 per share. This compares to earnings of $10.12 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +1.14%. A quarter ago, it was expected that this prescription drug distributor would post earnings of $9.31 per share when it actually produced earnings of $9.34, delivering a surprise of +0.32%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

McKesson, which belongs to the Zacks Medical - Dental Supplies industry, posted revenues of $96.3 billion for the quarter ended March 2026, missing the Zacks Consensus Estimate by 5.52%. This compares to year-ago revenues of $90.82 billion. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

McKesson shares have lost about 9.3% since the beginning of the year versus the S&P 500's gain of 7.6%.

What's Next for McKesson?While McKesson has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for McKesson was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $9.68 on $106.4 billion in revenues for the coming quarter and $44.24 on $442.8 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Dental Supplies is currently in the top 21% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Staar Surgical (STAA - Free Report) , is yet to report results for the quarter ended March 2026. The results are expected to be released on May 13.

This maker of implantable lenses is expected to post quarterly earnings of $0.13 per share in its upcoming report, which represents a year-over-year change of +125%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Staar Surgical's revenues are expected to be $91.8 million, up 115.5% from the year-ago quarter.
2026-06-12 19:38 3mo ago
2026-05-07 19:01 4mo ago
Compared to Estimates, McKesson (MCK) Q4 Earnings: A Look at Key Metrics
MCK McKesson
FMP Stock News
Original source text
McKesson (MCK - Free Report) reported $96.3 billion in revenue for the quarter ended March 2026, representing a year-over-year increase of 6%. EPS of $11.69 for the same period compares to $10.12 a year ago.

The reported revenue represents a surprise of -5.52% over the Zacks Consensus Estimate of $101.92 billion. With the consensus EPS estimate being $11.56, the EPS surprise was +1.14%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how McKesson performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Revenue- North American Pharmaceutical: $79.12 billion versus the three-analyst average estimate of $84.12 billion. The reported number represents a year-over-year change of -4.9%.Revenue- Medical-Surgical Solutions: $2.87 billion versus the three-analyst average estimate of $2.94 billion. The reported number represents a year-over-year change of +0.5%.Revenue- Prescription Technology Solutions: $1.5 billion versus the three-analyst average estimate of $1.47 billion. The reported number represents a year-over-year change of +11.7%.Revenue- Oncology & Multispecialty: $12.71 billion versus $12.69 billion estimated by three analysts on average.Revenue- Other: $101 million versus $69.63 million estimated by two analysts on average.Adjusted Operating Profit- Oncology & Multispecialty: $385 million compared to the $392.25 million average estimate based on three analysts.Adjusted Operating Profit- Medical-Surgical Solutions: $271 million compared to the $284.53 million average estimate based on three analysts.Adjusted Operating Profit- North American Pharmaceutical: $980 million versus $991.34 million estimated by three analysts on average.Adjusted Operating Profit- Prescription Technology Solutions: $322 million compared to the $310.2 million average estimate based on three analysts.Adjusted Operating Profit- Corporate: $-209 million versus the two-analyst average estimate of $-197.04 million.Adjusted Operating Profit- Other: $8 million compared to the $4.09 million average estimate based on two analysts.View all Key Company Metrics for McKesson here>>>

Shares of McKesson have returned -14.6% over the past month versus the Zacks S&P 500 composite's +11.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
2026-06-12 19:38 3mo ago
2026-05-07 21:01 4mo ago
McKesson Corporation (MCK) Q4 2026 Earnings Call Transcript
MCK McKesson
FMP Stock News
Original source text
McKesson Corporation (MCK) Q4 2026 Earnings Call Transcript
2026-06-12 19:38 3mo ago
2026-05-08 11:51 4mo ago
MCK Stock Falls Despite Q4 Earnings Beat, Sales Miss, Margins Up
MCK McKesson
FMP Stock News
Original source text
Key Takeaways MCK beat Q4 EPS estimates as oncology and specialty distribution fueled operational growth.McKesson's Q4 revenues rose 6%, but missed estimates despite higher prescription volumes.MCK expects fiscal 2027 adjusted EPS growth of 12-14% with revenue growth of 5-9%. McKesson Corporation (MCK - Free Report) reported fourth-quarter fiscal 2026 adjusted earnings per share (EPS) of $11.69, which beat the Zacks Consensus Estimate of $11.56 by 1.1%. The bottom line improved 15.5% on a year-over-year basis. The EPS growth was driven by strong operational improvement across the business, including contributions from acquisitions in the Oncology & Multispecialty segment.

GAAP EPS was $13.71 compared with $10.01 in the year-ago quarter. The significant improvement in EPS was due to a pre-tax credit within the North American Pharmaceutical segment related to the Rite Aid bankruptcy.

For fiscal 2026, adjusted EPS was up 18.3% to $39.11 while GAAP EPS gained 49.2% to $38.38.

Revenue DetailsRevenues of $96.3 billion missed the Zacks Consensus Estimate by 5.5%. The top line gained 6% year over year, primarily driven by increased prescription volumes from retail national account customers and growth in the distribution of oncology and specialty products, including contributions from the Oncology & Multispecialty segment. These were partially offset by lower contributions from branded pharmaceuticals.

Higher contributions from the Prescription Technology Solutions segment also aided the top line.

For fiscal 2026, revenues amounted to $403.43 billion, gaining 12.4% year over year.

Shares of MCK were down 0.4% in the after-hours trading on May 7, following mixed results. The company’s shares have lost 9.7% so far this year compared with the industry’s 10.4% decline. The S&P 500 Index has increased 8.6% in the same time frame.

Image Source: Zacks Investment Research

Q4 Segmental AnalysisThe company started reporting under new reportable segments and organizational structure, effective from the second quarter of fiscal 2026. The current reporting segments are North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions and Medical-Surgical Solutions.

Revenues from the North American Pharmaceutical segment totaled $79.12 billion, up 3% year over year. Per management, the upside was primarily driven by increased prescription volumes, including higher volumes from specialty products, partially offset by lower contributions from branded pharmaceuticals.

The U.S. Pharmaceutical and Specialty Solutions segment reported an adjusted operating profit of $980 million, up 11% from the prior-year quarter’s level. This was due to growth in the distribution of specialty products to health systems.

Revenues from the Oncology & Multispecialty segment amounted to $12.71 billion, up 31% year over year. This improvement can be attributed to growth in provider solutions and specialty distribution, and contributions from acquisitions.

Adjusted operating profit at the segment totaled $385 million, up 53% from the year-ago reported figure.

Revenues from the Prescription Technology Solutions segment totaled $1.5 billion, up 12% year over year. This uptick was due to increased prescription volumes in the third-party logistics and technology services businesses.

The segment reported an adjusted operating profit of $322 million, up 13% year over year, driven by higher demand for access solutions.

Revenues from the Medical-Surgical Solutions segment totaled $2.87 billion, up 1% year over year. Sales were driven by higher volumes of specialty pharmaceuticals, partially offset by lower contributions from the ambulatory care channel.

The Medical-Surgical segment reported an adjusted operating profit of $271 million, up 1% year over year, driven by cost optimization. This was partially offset by lower contributions from the ambulatory care channel.

MarginsAdjusted gross profit in the reported quarter was $3.86 billion, up 14% on a year-over-year basis. The figure represented 4.01% of net revenues, up nearly 28 basis points (bps) year over year.

The company reported an adjusted operating income of $1.97 billion, up 14.6% from the year-ago quarter’s figure. Operating margin was 2.04%, expanding nearly 15 bps year over year.

Financial UpdateCash and cash equivalents totaled $3.98 billion compared with $2.96 billion in the third quarter of fiscal 2026.

Cumulative net cash provided by operating activities amounted to $6.16 billion against cumulative net cash used in operating activities of $6.09 billion in the year-earlier period.

Fiscal 2027 GuidanceMcKesson issued its EPS and sales guidance for fiscal 2027. The company expects adjusted EPS to improve 12-14% to $43.80-$44.60. It anticipates total revenues to grow 5-9%.

MCK expects North American Pharmaceutical segment sales to grow 4-8%, with operating profit projected to improve 5.5-9.5%. Sales from the Oncology and Multispecialty segment are estimated to grow 14.5-18.5%, with operating profit projected to improve 13.5-17.5%. In the Prescription Technology Solutions segment, MCK anticipates revenue growth of 2.5% to 6.5% and operating profit growth of 11% to 15%. MCK anticipates revenue growth of 1% to 6%. It expects operating profit to range from flat to up 4% for the Medical-Surgical Solutions segment.

Summing UpMcKesson exited the fourth quarter of fiscal 2026 on a mixed note, with earnings beating estimates but sales missing the same.However, the company’s quarterly performance remained broad-based, with contributions from all major segments. Specialty distribution was again a standout, supported by strong volumes and continued market share gains in community oncology.

MCK’s oncology and multispecialty platforms, along with its expanding suite of biopharma services programs, continue to drive customer demand. The portfolio transformation also advanced, with progress toward separating the Medical-Surgical Solutions business and continued momentum from recent acquisitions in oncology and eye care. MCK expects to complete the spin-off of the Medical-Surgical Solutions business in the second half of calendar 2027. The company also completed the divestiture of its retail and distribution businesses in Norway, marking the final phase of its exit from European operations.

MCK’s Zacks Rank and Stocks to ConsiderMcKesson currently has a Zacks Rank #3 (Hold).

Some better-ranked stocks in the broader medical space that have announced quarterly results are West Pharmaceutical Services, Inc. (WST - Free Report) , Intuitive Surgical (ISRG - Free Report) and Cardinal Health, Inc. (CAH - Free Report) .

West Pharmaceutical reported first-quarter 2026 earnings per share (EPS) of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

West Pharmaceutical has a long-term estimated growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.37%.

Intuitive Surgical reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.19%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%. It currently carries a Zacks Rank of 2 (Buy).

Intuitive Surgical has a long-term estimated growth rate of 14.9%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.82%.

Cardinal Health, carrying a Zacks Rank of 2 at present, reported third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%.

Cardinal Health has a long-term estimated growth rate of 15.6%. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.27%.
2026-06-12 19:38 3mo ago
2026-05-11 15:09 4mo ago
McKesson Q4 Earnings Call Highlights
MCK McKesson
FMP Stock News
Original source text
2 hours ago

MSA Safety Incorporporated (NYSE:MSA) CFO Acquires $71,093.12 in StockMarketBeat

MSA Safety Incorporporated (NYSE:MSA - Get Free Report) CFO Julie Beck bought 448 shares of the stock in a transaction dated Thursday, June 11th. The stock was acquired at an average price of $158.69 per share, with a total value of $71,093.12. Following the completion of the purchase, the chief financial officer owned 3,825 shares of the company's stock, valued at $606,989.25. This represents a 13.27% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

NYSE:MSA

Read MSA Safety Incorporporated (NYSE:MSA) CFO Acquires $71,093.12 in Stock

2 hours ago

Insider Selling: NBT Bancorp (NASDAQ:NBTB) Director Sells 2,100 Shares of StockMarketBeat

NBT Bancorp Inc. (NASDAQ:NBTB - Get Free Report) Director Heidi Hoeller sold 2,100 shares of the business's stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $48.03, for a total transaction of $100,863.00. Following the transaction, the director owned 11,560 shares of the company's stock, valued at approximately $555,226.80. This represents a 15.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

NASDAQ:NBTB

Read Insider Selling: NBT Bancorp (NASDAQ:NBTB) Director Sells 2,100 Shares of Stock

2 hours ago

Douglas Milne Sells 1,600 Shares of IGM Financial (TSE:IGM) StockMarketBeat

IGM Financial Inc. (TSE:IGM - Get Free Report) Director Douglas Milne sold 1,600 shares of the business's stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of C$80.61, for a total value of C$128,976.00. Following the sale, the director directly owned 800 shares in the company, valued at C$64,488. The trade was a 66.67% decrease in their ownership of the stock.

TSE:IGM

Read Douglas Milne Sells 1,600 Shares of IGM Financial (TSE:IGM) Stock

2 hours ago

GlobalFoundries (NASDAQ:GFS) Insider Michael James Hogan Sells 2,800 SharesMarketBeat

GlobalFoundries Inc. (NASDAQ:GFS - Get Free Report) insider Michael James Hogan sold 2,800 shares of GlobalFoundries stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $75.17, for a total value of $210,476.00. Following the transaction, the insider owned 6,695 shares in the company, valued at $503,263.15. This trade represents a 29.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

NASDAQ:GFS

Read GlobalFoundries (NASDAQ:GFS) Insider Michael James Hogan Sells 2,800 Shares

Sort By

Time Frame

Alert Type

Keywords

Page 1 of 325
2026-06-12 19:38 3mo ago
2026-05-12 15:10 4mo ago
McKesson Corporation (MCK) Presents at Bank of America Global Healthcare Conference 2026 Transcript
MCK McKesson
FMP Stock News
Original source text
McKesson Corporation (MCK) Presents at Bank of America Global Healthcare Conference 2026 Transcript
2026-06-12 19:38 3mo ago
2026-05-14 10:01 3mo ago
McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know
MCK McKesson
FMP Stock News
Original source text
McKesson (MCK - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Shares of this prescription drug distributor have returned -14.6% over the past month versus the Zacks S&P 500 composite's +8.6% change. The Zacks Medical - Dental Supplies industry, to which McKesson belongs, has lost 10.5% over this period. Now the key question is: Where could the stock be headed in the near term?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Revisions to Earnings EstimatesHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

McKesson is expected to post earnings of $9.48 per share for the current quarter, representing a year-over-year change of +14.8%. Over the last 30 days, the Zacks Consensus Estimate has changed -0.7%.

The consensus earnings estimate of $44.29 for the current fiscal year indicates a year-over-year change of +13.2%. This estimate has changed +0.1% over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $49.94 indicates a change of +12.8% from what McKesson is expected to report a year ago. Over the past month, the estimate has changed +0.2%.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, McKesson is rated Zacks Rank #3 (Hold).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Projected Revenue GrowthEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

For McKesson, the consensus sales estimate for the current quarter of $104.95 billion indicates a year-over-year change of +7.3%. For the current and next fiscal years, $434.7 billion and $466.78 billion estimates indicate +7.8% and +7.4% changes, respectively.

Last Reported Results and Surprise HistoryMcKesson reported revenues of $96.3 billion in the last reported quarter, representing a year-over-year change of +6%. EPS of $11.69 for the same period compares with $10.12 a year ago.

Compared to the Zacks Consensus Estimate of $101.92 billion, the reported revenues represent a surprise of -5.52%. The EPS surprise was +1.12%.

The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates two times over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

McKesson is graded A on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about McKesson. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
2026-06-12 19:38 3mo ago
2026-05-22 13:21 3mo ago
Here's Why You Should Retain McKesson Stock in Your Portfolio for Now
MCK McKesson
FMP Stock News
Original source text
Key Takeaways McKesson posted strong Q4 fiscal 2026 results, led by specialty distribution and oncology growth.MCK's oncology platform saw 35% revenue growth as provider additions boosted scale and services.McKesson faces IRA-related pricing pressure and weaker Medical-Surgical segment growth. McKesson (MCK - Free Report) reported strong fourth-quarter fiscal 2026 results, driven by robust growth in specialty distribution, oncology services and biopharma solutions. Earnings expansion benefited from ongoing operational efficiency and capital discipline, despite persistent margin pressures and volatility across certain segments.

Shares of this Zacks Rank #3 (Hold) company have lost 6.6% so far this year compared with the industry's 9.3% decline. The S&P 500 has increased 9.2% in the said time frame.

MCK is one of the leading pharmaceutical distributors in North America, with a market capitalization of $90.72 billion. It forecasts 13.2% growth in fiscal 2027 and aims to sustain its strong performance going forward. The company’s earnings surpassed estimates in each of the trailing four quarters, the average beat being 3.09%.

Image Source: Zacks Investment Research

Factors Favoring MCK StockOncology and Multispecialty Platform Become a High-Growth Engine: McKesson’s oncology and multispecialty business is increasingly emerging as the company’s primary structural growth driver, with segment revenues rising 35% in the fourth quarter of fiscal 2026 and operating profit surging 53%.

Excluding acquisitions, organic operating profit still increased a solid 13%, highlighting sustained underlying demand rather than acquisition-driven growth alone. Expansion continues to be driven by provider additions, specialty drug distribution and greater integration of technology and analytics capabilities through Ontada and AI-enabled physician tools.

With the U.S. Oncology Network adding more than 570 providers in fiscal 2026, the largest increase since 2010, McKesson is building a scaled community-care ecosystem that strengthens both distribution economics and recurring service revenues.

Strong Specialty Pharmaceutical Momentum: McKesson continues to benefit from secular growth in specialty pharmaceuticals, particularly oncology, biologics and GLP-1 therapies, which remain among the fastest-growing categories in healthcare. In the fiscal fourth quarter, North American Pharmaceutical operating profit increased 11%, supported by specialty distribution growth and health system demand despite branded drug pricing pressure.

GLP-1 distribution revenues reached $14 billion in the quarter, up 22% year over year, underscoring the scale of the category. Management emphasized that lower branded pricing and sequential GLP-1 moderation had no operating profit impact, demonstrating the resilience of McKesson’s fee-based economics. This strengthens visibility into long-term earnings growth even amid drug pricing volatility.

Prescription Technology Solutions Holds Potential: McKesson’s Prescription Technology Solutions (RxTS) business is benefiting from rising drug complexity, affordability challenges and prior authorization requirements, particularly for specialty medications and GLP-1 therapies. The segment revenues increased 12% in the fiscal fourth quarter, while operating profit grew 13%, driven by robust demand for access and affordability services.

Management highlighted support for 3.4 million patients during the annual verification season, alongside rising productivity driven by automation and AI initiatives. McKesson also launched an integrated specialty access platform that combines benefits verification, prior authorization and affordability support within a single workflow.

As healthcare administration becomes increasingly complex, McKesson’s scale and digital connectivity are strengthening its competitive moat, which should help sustain double-digit profit growth.

Factors That May Offset the Gains for MCKIRA-Driven Drug Pricing Pressure Creates Top-Line Headwinds: McKesson faces growing exposure to pharmaceutical pricing reform, particularly through the Inflation Reduction Act (IRA) and branded drug price reductions. Management disclosed that manufacturer price declines reduced North American Pharmaceutical revenue growth by approximately 3 percentage points in the fourth quarter of fiscal 2026, with additional pressure expected in fiscal 2027.

While the company emphasized that distribution economics remain intact due to fee-based contracts, sustained price compression could suppress reported revenue growth and reduce investor perception of underlying business momentum. Since McKesson distributes high-dollar specialty therapies, lower drug prices can materially affect top-line performance even when operating profits remain resilient.

Medical-Surgical Business Faces Margin and Growth Constraints: McKesson’s Medical-Surgical Solutions segment continues to underperform relative to its faster-growing specialty platforms. The fiscal fourth-quarter operating profit declined 5%, led by weaker illness-season demand, including vaccines and diagnostic testing, while revenues increased only 1%.

Although the planned separation unlocked value, the business remains exposed to lower-growth ambulatory care channels, product demand cyclicality and operational execution risks during carve-out. Management expects operating profit in fiscal 2027 to be flat to up only 4%, suggesting continued profitability constraints. Execution missteps during separation or weaker-than-expected standalone performance could reduce shareholder value creation.

RxTS Growth Becoming Less Predictable: While Prescription Technology Solutions continues to be a high-growth segment, management noted rising earnings volatility due to pharmaceutical launch timing, payer utilization trends, formulary shifts, and program transitions. The segment’s 3PL operations represent about 55% of total revenue, making quarterly results sensitive to new drug introductions and changes in manufacturer support programs.

Management also cautioned that fiscal 2027 revenue and operating trends may not progress linearly, adding near-term uncertainty despite strong long-term growth drivers. As therapies mature or move into lower-support phases, growth may become more uneven and harder to predict.

Estimate Trends for MCKMcKesson is witnessing a positive estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for its earnings per share has improved 3 cents to $44.29.

The Zacks Consensus Estimate for the company’s first-quarter fiscal 2027 revenues and earnings per share is pegged at $104.95 billion and $9.48, respectively. The estimate for revenues indicates a 7.3% improvement from the year-ago quarter’s reported number, while that for earnings implies a 14.8% gain.

Stocks to ConsiderSome better-ranked stocks from the same medical industry are Pacific Biosciences of California (PACB - Free Report) , Globus Medical (GMED - Free Report) and Biodesix (BDSX - Free Report) .

Pacific Biosciences of California, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted loss per share of 12 cents, which surpassed the Zacks Consensus Estimate by 29.4%. Revenues of $37 million missed the Zacks Consensus Estimate by 9.3%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

PACB’s earnings are estimated to decline at a rate of 12.2% against the industry’s 16.9% growth in 2027. The company beat earnings estimates in each of the trailing four quarters, with the average surprise being 29.76%.

Globus Medical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $1.12, which outpaced the Zacks Consensus Estimate by 21.7%. Revenues of $760 million surpassed the Zacks Consensus Estimate by 4%.

GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% rise. The company beat earnings estimates in each of the trailing four quarters, with the average surprise being 26.26%.

Biodesix, currently carrying a Zacks Rank of 2, reported a first-quarter 2026 adjusted loss per share of 81 cents, which beat the Zacks Consensus Estimate by 35.71%. Revenues of $26 million beat the Zacks Consensus Estimate by 12.3%.

BDSX has an estimated earnings growth rate of 36% for 2026 compared with the industry’s 13.4% rise. The company beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 25.56%.
2026-06-12 19:38 3mo ago
2026-05-27 10:00 3mo ago
McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on It
MCK McKesson
FMP Stock News
Original source text
McKesson (MCK - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Shares of this prescription drug distributor have returned -9.7% over the past month versus the Zacks S&P 500 composite's +5.1% change. The Zacks Medical - Dental Supplies industry, to which McKesson belongs, has lost 4.9% over this period. Now the key question is: Where could the stock be headed in the near term?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Revisions to Earnings EstimatesHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.

Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.

For the current quarter, McKesson is expected to post earnings of $9.48 per share, indicating a change of +14.8% from the year-ago quarter. The Zacks Consensus Estimate has changed -0.7% over the last 30 days.

The consensus earnings estimate of $44.29 for the current fiscal year indicates a year-over-year change of +13.2%. This estimate has changed +0.1% over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $49.94 indicates a change of +12.8% from what McKesson is expected to report a year ago. Over the past month, the estimate has changed +0.2%.

With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for McKesson.

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Revenue Growth ForecastEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

For McKesson, the consensus sales estimate for the current quarter of $104.95 billion indicates a year-over-year change of +7.3%. For the current and next fiscal years, $434.7 billion and $466.78 billion estimates indicate +7.8% and +7.4% changes, respectively.

Last Reported Results and Surprise HistoryMcKesson reported revenues of $96.3 billion in the last reported quarter, representing a year-over-year change of +6%. EPS of $11.69 for the same period compares with $10.12 a year ago.

Compared to the Zacks Consensus Estimate of $101.92 billion, the reported revenues represent a surprise of -5.52%. The EPS surprise was +1.12%.

The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates two times over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

McKesson is graded A on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about McKesson. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
2026-06-12 19:38 3mo ago
2026-06-02 08:00 3mo ago
McKesson Closes Strategic Investment with Apollo Funds for Minority Interest in Medical-Surgical Solutions
MCK McKesson
FMP Stock News
Original source text
-

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) announced today the successful completion of the previously announced minority ownership interest investment from funds managed by affiliates of Apollo (“Apollo Funds”) in McKesson’s Medical-Surgical Solutions (“MMS”) business on June 1, 2026. This transaction represents a key milestone in McKesson’s intention to separate MMS into an independent, publicly traded company, and positions the business for long-term growth.

Apollo Funds invested $1.25 billion in convertible preferred equity of MMS to acquire an approximately 13% interest in MMS. The transaction values MMS at approximately $13 billion total enterprise valuation. McKesson retains operating control and majority ownership of MMS and will consolidate the results for financial reporting.

Cautionary Statements

Statements in this press release about McKesson's intent to separate MMS into an independent company, the planned initial public offering (“IPO”) of MMS, and the expected benefits of the transactions described, including anticipated timing, plans, expectations, commitments and intentions, constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Readers should not place undue reliance on forward-looking statements, which speak only as of the date they are first made. Except to the extent required by law, the company undertakes no obligation to publicly update forward-looking statements.

Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated, or implied. Although it is not possible to predict or identify all such risks and uncertainties, risk factors include, but are not limited to: the planned separation and IPO of MMS are contingent upon the satisfaction of certain conditions, may not be completed on the currently contemplated terms or timeline, or at all, and, if completed, may not achieve the intended financial and strategic benefits; unanticipated business, market, governmental, or other developments could delay or prevent the separation, or the IPO, or cause any of the transactions to occur on less favorable terms; the transactions described are subject to conditions that may not be satisfied on the expected timeline, or at all, which could delay or prevent closing; we may be unsuccessful in achieving our strategic growth objectives; we might be adversely impacted by changes in the economic environments in which we operate; and we might be adversely impacted by events outside of our control, such as widespread public health issues, natural disasters, political events, and other catastrophic events. We encourage investors to read the important risk factors described in McKesson’s most recent Form 10-K filed with the Securities and Exchange Commission.

About McKesson Corporation

McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Stories & Insights.

About Apollo

Apollo is a high-growth, global alternative asset manager. Apollo’s asset management business seeks to provide its clients excess return at every point along the risk-reward spectrum from investment grade credit to private equity. For more than three decades, Apollo’s investing expertise across its fully integrated platform has served the financial return needs of its clients and provided businesses with innovative capital solutions for growth. Athene, Apollo’s retirement services business, specializes in helping clients achieve financial security by providing a suite of retirement savings products and acting as a solutions provider to institutions. Apollo’s patient, creative, and knowledgeable approach to investing aligns its clients, the businesses it invests in, its employees, and the communities it impacts, to expand opportunity and achieve positive outcomes. As of March 31, 2026, Apollo had approximately $1.03 trillion of assets under management. To learn more, please visit www.apollo.com.

More News From McKesson Corporation

Back to Newsroom
2026-06-12 19:38 3mo ago
2026-06-08 10:51 3mo ago
Why McKesson (MCK) is a Top Momentum Stock for the Long-Term
MCK McKesson
FMP Stock News
Original source text
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.

It also includes access to the Zacks Style Scores.

What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.

Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.

The Style Scores are broken down into four categories:

Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.

Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.

Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.

It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.

That's where the Style Scores come in.

To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.

As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.

For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: McKesson (MCK - Free Report) McKesson Corporation, headquartered in Irving, TX, is one of the largest global healthcare companies and the leading pharmaceutical distributor in North America. The company operates across four business segments: U.S. Pharmaceutical, which distributes branded, generic, and specialty drugs; RxTS, which provides patient access, affordability, and third-party logistics services for biopharma manufacturers and payors; Medical-Surgical Solutions, supplying alternate-site providers such as physician offices and home health; and International, primarily focused in Canada. Specialty pharmaceuticals, oncology services, and GLP-1 medications for diabetes and obesity are key growth engines. In FY25, GLP-1 revenues alone reached nearly $41 billion.

MCK is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.

Momentum investors should take note of this Medical stock. MCK has a Momentum Style Score of B, and shares are up 5.4% over the past four weeks.

Four analysts revised their earnings estimate higher in the last 60 days for fiscal 2027, while the Zacks Consensus Estimate has increased $0.06 to $44.28 per share. MCK also boasts an average earnings surprise of +3.1%.

With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, MCK should be on investors' short list.
2026-06-12 19:38 3mo ago
2026-06-09 10:41 3mo ago
Here's Why McKesson (MCK) is a Strong Value Stock
MCK McKesson
FMP Stock News
Original source text
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.

Zacks Premium includes access to the Zacks Style Scores as well.

What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.

Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.

Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.

VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.

How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.

That's where the Style Scores come in.

To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.

Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.

For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: McKesson (MCK - Free Report) McKesson Corporation, headquartered in Irving, TX, is one of the largest global healthcare companies and the leading pharmaceutical distributor in North America. The company operates across four business segments: U.S. Pharmaceutical, which distributes branded, generic, and specialty drugs; RxTS, which provides patient access, affordability, and third-party logistics services for biopharma manufacturers and payors; Medical-Surgical Solutions, supplying alternate-site providers such as physician offices and home health; and International, primarily focused in Canada. Specialty pharmaceuticals, oncology services, and GLP-1 medications for diabetes and obesity are key growth engines. In FY25, GLP-1 revenues alone reached nearly $41 billion.

MCK is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.

It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 17.31; value investors should take notice.

For fiscal 2027, four analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.06 to $44.28 per share. MCK boasts an average earnings surprise of +3.1%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, MCK should be on investors' short list.
2026-06-12 19:38 3mo ago
2026-06-10 10:01 3mo ago
McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know
MCK McKesson
FMP Stock News
Original source text
McKesson (MCK - Free Report) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.

Shares of this prescription drug distributor have returned +6.7% over the past month versus the Zacks S&P 500 composite's no change. The Zacks Medical - Dental Supplies industry, to which McKesson belongs, has gained 7.5% over this period. Now the key question is: Where could the stock be headed in the near term?

While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.

Earnings Estimate RevisionsHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For the current quarter, McKesson is expected to post earnings of $9.63 per share, indicating a change of +16.6% from the year-ago quarter. The Zacks Consensus Estimate has changed -0% over the last 30 days.

For the current fiscal year, the consensus earnings estimate of $44.28 points to a change of +13.2% from the prior year. Over the last 30 days, this estimate has remained unchanged.

For the next fiscal year, the consensus earnings estimate of $49.95 indicates a change of +12.8% from what McKesson is expected to report a year ago. Over the past month, the estimate has changed +0.1%.

With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for McKesson.

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Revenue Growth ForecastEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

In the case of McKesson, the consensus sales estimate of $104.39 billion for the current quarter points to a year-over-year change of +6.7%. The $432.83 billion and $464.69 billion estimates for the current and next fiscal years indicate changes of +7.3% and +7.4%, respectively.

Last Reported Results and Surprise HistoryMcKesson reported revenues of $96.3 billion in the last reported quarter, representing a year-over-year change of +6%. EPS of $11.69 for the same period compares with $10.12 a year ago.

Compared to the Zacks Consensus Estimate of $101.92 billion, the reported revenues represent a surprise of -5.52%. The EPS surprise was +1.12%.

The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates two times over this period.

ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

McKesson is graded B on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about McKesson. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
2026-06-12 19:38 3mo ago
2026-04-27 04:02 4mo ago
Aprio Wealth Management LLC Increases Stake in Capital One Financial Corporation $COF
COF Capital One Financial
FMP Stock News
Original source text
Posted by Defense World Staff on Apr 27th, 2026

Aprio Wealth Management LLC lifted its stake in shares of Capital One Financial Corporation (NYSE:COF) by 72.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 6,513 shares of the financial services provider’s stock after buying an additional 2,739 shares during the quarter. Aprio Wealth Management LLC’s holdings in Capital One Financial were worth $1,579,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. D.A. Davidson & CO. grew its stake in shares of Capital One Financial by 4.4% during the fourth quarter. D.A. Davidson & CO. now owns 71,497 shares of the financial services provider’s stock worth $17,328,000 after purchasing an additional 2,992 shares in the last quarter. Kestra Private Wealth Services LLC increased its holdings in Capital One Financial by 0.9% in the fourth quarter. Kestra Private Wealth Services LLC now owns 19,091 shares of the financial services provider’s stock valued at $4,627,000 after buying an additional 177 shares during the last quarter. Physician Wealth Advisors Inc. raised its stake in Capital One Financial by 15.1% in the fourth quarter. Physician Wealth Advisors Inc. now owns 388 shares of the financial services provider’s stock valued at $94,000 after buying an additional 51 shares in the last quarter. Deltec Asset Management LLC acquired a new stake in Capital One Financial in the fourth quarter valued at $1,285,000. Finally, Inscription Capital LLC lifted its holdings in Capital One Financial by 3.9% during the 4th quarter. Inscription Capital LLC now owns 1,858 shares of the financial services provider’s stock worth $450,000 after buying an additional 70 shares during the last quarter. 89.84% of the stock is currently owned by hedge funds and other institutional investors.

Capital One Financial Stock Up 0.0% Shares of NYSE COF opened at $191.43 on Monday. The stock has a market cap of $119.06 billion, a PE ratio of 67.17, a price-to-earnings-growth ratio of 0.70 and a beta of 1.14. The company has a quick ratio of 1.03, a current ratio of 1.03 and a debt-to-equity ratio of 0.46. Capital One Financial Corporation has a 52-week low of $174.72 and a 52-week high of $259.64. The business has a 50-day moving average price of $191.66 and a 200 day moving average price of $213.90.

Capital One Financial (NYSE:COF – Get Free Report) last released its quarterly earnings results on Tuesday, April 21st. The financial services provider reported $4.42 EPS for the quarter, missing the consensus estimate of $5.08 by ($0.66). Capital One Financial had a return on equity of 10.59% and a net margin of 4.29%.The firm had revenue of $15.23 billion for the quarter, compared to analyst estimates of $15.68 billion. During the same period last year, the firm earned $4.06 EPS. The company’s quarterly revenue was up 52.3% on a year-over-year basis. Equities research analysts forecast that Capital One Financial Corporation will post 19.17 earnings per share for the current year.

Capital One Financial Announces Dividend The firm also recently announced a quarterly dividend, which was paid on Monday, March 2nd. Stockholders of record on Thursday, February 19th were given a dividend of $0.80 per share. The ex-dividend date was Thursday, February 19th. This represents a $3.20 dividend on an annualized basis and a dividend yield of 1.7%. Capital One Financial’s dividend payout ratio (DPR) is 112.28%.

Insider Buying and Selling at Capital One Financial In other news, insider Lia Dean sold 3,284 shares of Capital One Financial stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $223.68, for a total value of $734,565.12. Following the transaction, the insider directly owned 70,162 shares of the company’s stock, valued at $15,693,836.16. The trade was a 4.47% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Neal Blinde sold 38,135 shares of the company’s stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $190.51, for a total transaction of $7,265,098.85. Following the completion of the sale, the insider owned 33,551 shares of the company’s stock, valued at approximately $6,391,801.01. This trade represents a 53.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 50,047 shares of company stock valued at $9,742,217. Insiders own 0.78% of the company’s stock.

Trending Headlines about Capital One Financial Here are the key news stories impacting Capital One Financial this week:

Positive Sentiment: BTIG reaffirmed a “Buy” on COF, providing analyst support that can help stabilize investor sentiment. BTIG Research Reaffirms “Buy” Rating for Capital One Financial Positive Sentiment: Capital One finalized the Brex acquisition and a related share resale, expanding its commercial card/embedded finance footprint — strategic M&A that could boost long‑term revenue diversification. Capital One Finalizes Brex Acquisition and Share Resale Positive Sentiment: Capital One closed a small Hopper tech/employee deal in April as it pursues travel‑related product expansion — a targeted tuck‑in that could support growth in travel card offerings. Capital One Closed Hopper Tech and Employee Deal in April, Focuses on Travel Expansion Neutral Sentiment: Argus trimmed its price target to $250 but kept a “Buy” rating — a modest downgrade that still implies upside from current levels. Argus Adjusts Price Target to $250, Maintains Buy Neutral Sentiment: Several market writeups and stock‑selection lists are discussing COF’s valuation and whether the recent pullback creates a buying opportunity — these are commentary pieces that may influence sentiment but don’t change fundamentals immediately. 3 Stocks That Might Be Undervalued S&P 500 Stock Buy/Avoid Coverage Negative Sentiment: Capital One missed Q1 consensus: EPS of $4.42 vs. ~$5.08 expected and revenue slightly below estimates — a near‑term earnings disappointment that directly pressures the stock. Capital One Missed Earnings and Truist Cut Its Target Negative Sentiment: Truist trimmed its price target (to $255) after the earnings miss — analyst target cuts amplify selling pressure even if ratings remain “Buy.” Truist Lowers Price Target Negative Sentiment: A judge approved a $425M settlement over 360 Savings account claims; payouts and any related reserve charges are a one‑time P&L hit and a headline risk that weighs on near‑term sentiment. Judge Approves $425 Million Capital One Settlement Analyst Ratings Changes Several research analysts have recently issued reports on COF shares. HSBC lowered their price objective on Capital One Financial from $234.00 to $226.00 and set a “hold” rating for the company in a research report on Tuesday, January 20th. Keefe, Bruyette & Woods boosted their target price on Capital One Financial from $260.00 to $290.00 and gave the stock an “outperform” rating in a research note on Friday, January 2nd. Jefferies Financial Group reaffirmed a “buy” rating and issued a $300.00 price target on shares of Capital One Financial in a report on Monday, March 16th. UBS Group dropped their price target on shares of Capital One Financial from $286.00 to $283.00 and set a “buy” rating on the stock in a research note on Tuesday, April 7th. Finally, Wall Street Zen cut shares of Capital One Financial from a “buy” rating to a “hold” rating in a report on Saturday, January 10th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have given a Hold rating to the company. According to MarketBeat, Capital One Financial has a consensus rating of “Moderate Buy” and an average price target of $258.86.

Read Our Latest Analysis on COF

About Capital One Financial (Free Report)

Capital One Financial Corporation (NYSE: COF) is a diversified bank holding company headquartered in McLean, Virginia. The company’s core businesses include credit card lending, consumer and commercial banking, and auto finance. Capital One issues a wide range of credit card products for consumers and small businesses, and it operates deposit and digital banking services aimed at retail customers and small to midsize enterprises.

Products and services include credit and charge cards, checking and savings accounts (including the online-focused Capital One 360 platform), auto loans, and commercial lending solutions.

Recommended Stories Five stocks we like better than Capital One Financial Want to see what other hedge funds are holding COF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Capital One Financial Corporation (NYSE:COF – Free Report).

Receive News & Ratings for Capital One Financial Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capital One Financial and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEInvesco S&P 500 Equal Weight ETF $RSP Shares Purchased by Aprio Wealth Management LLC

NEXT HEADLINE »Aprio Wealth Management LLC Purchases 4,750 Shares of Micron Technology, Inc. $MU
2026-06-12 19:38 3mo ago
2026-04-29 09:07 4mo ago
Current 1031 Introduces 3% Interest on All Exchange Funds, Held with Capital One
COF Capital One Financial
FMP Stock News
Original source text
-

A $10 million exchange held for the full 180 days earns approximately $147,000 in interest, paid directly to the investor.

MANHATTAN BEACH, Calif.--(BUSINESS WIRE)--Current 1031, a Qualified Intermediary (QI) founded by veteran real estate and finance professionals, today announced a 3% interest rate on all client exchange funds, with no size tiers or minimums. Interest is generally paid at the conclusion of the exchange.

A 1031 exchange allows real estate investors to defer capital gains taxes by reinvesting sale proceeds into a like-kind replacement property within 180 days. During that period, exchange funds are held by a Qualified Intermediary. At a 3% interest rate, a $10 million exchange held for the full 180-day period would accrue approximately $147,000 in interest; a $25 million transaction would accrue approximately $369,000 over the same window. Current 1031 charges a flat fee of $1,500 per exchange with no hidden costs.

“Every dollar sitting in an exchange account should be working for the investor, not sitting idle,” said Brad Wetherby, co-founder of Current 1031. “With 3% interest on exchange funds, we are putting real, meaningful money back into the hands of our clients.”

A Resource Built for Real Estate Brokers and Advisors

For most real estate brokers, the QI conversation happens at the end of a transaction. Current 1031 moves that conversation to the beginning. When a broker introduces a QI that provides a 3% interest rate on exchange funds, that broker provides a quantifiable benefit to the client that strengthens the broker’s advisory relationship.

About Current 1031

Current 1031, LLC is a Qualified Intermediary facilitating IRC Section 1031 like-kind exchanges nationwide. The firm holds all exchange funds in segregated accounts at a major institution and pays 3% interest on every client exchange, with no size tiers or minimums. Founded by veteran real estate and investment professionals, Current 1031 combines institutional-grade fund security, experienced guidance, and flat-fee pricing. Learn more at current1031.com.

Disclaimer: Current 1031 does not provide legal or tax advice. Investors should consult their own tax and legal advisors regarding 1031 exchanges and related matters. Interest rates are subject to change.

Back to Newsroom
2026-06-12 19:38 3mo ago
2026-05-06 13:46 4mo ago
Capital One's Big Bet Faces Rising Credit Risk
COF Capital One Financial
FMP Stock News
Original source text
It’s complicated, but just you wait. That’s the message from Capital One NYSE: COF in light of its first-quarter results as it undertakes a significant rejiggering of its business.

For many investors, that’s not been a convincing argument. The lender’s stock has fallen more than one-third since early January. But analysts expect the shares to rebound. Investors trying to decide whether the recent selloff is a red flag or a buying opportunity need to pick through the numbers carefully.

Get Capital One Financial alerts:

Capital One's Road to Payments GiantCapital One is arguably one of the most closely watched bets in American banking. When the company completed its takeover of Discover in May 2025, it bought more than a credit card company. It got its own payments network.

Capital One Financial Today

COF

Capital One Financial

$184.14 +2.10 (+1.15%)

As of 03:38 PM Eastern

This is a fair market value price provided by Massive. Learn more.

52-Week Range$174.24▼

$259.64Dividend Yield1.74%

P/E Ratio64.63

Price Target$258.75

Instead of running its cards on the Visa NYSE: V or Mastercard NYSE: MA platforms, which charge merchants interchange fees, Capital One can route transactions on its own rails, potentially saving billions over time.

The combined company now lands solidly among the top four payment networks in purchase volume with Visa, Mastercard, and American Express NYSE: AXP.

From the deal, management has promised more than $2.5 billion in annual synergies, including $1.5 billion from cost savings and $1.2 billion from network efficiencies.

Much of that might not show up until 2027, after the planned technology merger and migration of customers.

That’s the idea, but the first-quarter results told a more complicated story.

Earnings Missed ExpectationsFor the first quarter, Capital One reported adjusted earnings of $4.42 per share, missing analyst expectations of $4.61 per share. Revenue surged 52.3% year-over-year to $15.23 billion, thanks in large part to the contribution of Discover. But even that fell short of Wall Street forecasts.

The number that caught much of the attention, though, was net interest margin, which sank to 7.87%, down 39 basis points from the prior quarter. That measure of the difference between what a bank earns on its loans and what it pays on deposits again disappointed.

For its part, the company blamed fewer calendar days in the first quarter compared with the last three months of 2025 and the seasonal impact of customers paying down debt after the holidays. But strong retail deposit growth and the impact of the company’s sale of the Discover Home Loans portfolio also factored in.

There was some good news. Earnings before the bank set aside reserves for potential troubled loans rose 8% quarter over quarter to $6.8 billion. And signs that integration was coming along led to non-interest expenses falling 9% to $8.5 billion, and marketing spend dropping 23%.

Credit Losses Keep ClimbingStill, other trends were troubling. Capital One’s provision for possible credit losses surged 72% YOY to $4.07 billion—again coming in higher than analyst estimates. Overall, net charge-offs reached $3.8 billion for the quarter, up 41% YOY.

This is not the direction investors wanted to see. Capital One’s core business is consumer credit cards, and its customers have historically skewed toward subprime and near-prime borrowers. Even with Discover’s more affluent consumer profile, stressed household budgets with elevated inflation and interest rates could keep Capital One’s loan losses eating into earnings.

In fact, management’s decision to build reserves by an additional $230 million, most notably in auto and consumer banking, could suggest possible tough conditions ahead.

Capital Levels Provide Some ProtectionThe company does have room to cushion surprises. Capital One’s Tier 1 capital ratio stands at a healthy 14.4% and is in line with many in the financial sector. And while the dividend yields just 1.7% annually on a payout of $3.20 per share, the board has approved a $16 billion buyback plan near the end of last year.

The bank’s efficiency ratio, which is a measure of how much it spends to generate each dollar of revenue. stood at 55.57%. That’s not bad for retail banks with large branch networks, but above the sub-50% levels enjoyed by many digital-first banks. Still, the level trended down from the previous and YOY quarters, and the gap suggests some redundancies still exist. The migration of Discover’s credit card customers onto Capital One’s technology platforms, if completed as planned, could provide some relief for these numbers.

The Discover Deal Must DeliverThe central question still is whether the Discover acquisition will deliver on its promises. The strategic logic of the Discover deal is clearly there. Owning a payment network may help expand the combined brands’ merchant acceptance globally, which is a lingering soft point, and could unlock substantial revenue.

But the integrations and cost savings need to arrive. That becomes even more interesting as Capital One also picked up another business in April when the lender closed on a $5 billion for Brex.

That additional strategic pivot moved the company even further beyond its traditional consumer business. Brex, a fintech platform that provides business payments and spend management services, delivers to Capital One an AI framework designed to automate accounting workflows. Beyond consumers, the purchase is a potentially neat fit for a lender to small businesses.

Capital One Financial Stock Forecast Today12-Month Stock Price Forecast:
$258.75
40.11% Upside

Moderate Buy
Based on 22 Analyst Ratings

Current Price$184.67High Forecast$310.00Average Forecast$258.75Low Forecast$215.00Capital One Financial Stock Forecast Details

Analysts Still Expect UpsideWith all the numbers and news to digest, analysts remain broadly bullish on the company, though some lowered their targets after the first quarter results.

As of now, the consensus rating on the stock is Moderate Buy, with an average price target of $258.14 implying roughly a one-third upside from current levels near $190. Price targets for 12 months range from $215 at the more cautious end to $310 at the most optimistic.

An agreement to pay $425 million to settle a class action suit alleging that Capital One had practiced deceptive marketing tactics also knocked the stock price in late April.

Investors Face a High-Risk BetFor investors, there’s obviously still much to consider. Capital One is a high-conviction bet wrapped in genuine near-term uncertainty. For investors with a two-year time horizon and a stomach for volatility, the current price near $190 may prove to be an attractive entry point.

The 30+% decline from a recent peak may have already priced in a meaningful amount of bad news. If credit quality stabilizes and integration milestones are met, the stock has clear room to recover toward analyst targets.

But the risks remain. The company’s 1.7% dividend yield is unremarkable for income investors. And credit losses are still rising, while questions over two integrations remain. If you enjoy the uncertainty of predictions markets, this stock may be for you.

Should You Invest $1,000 in Capital One Financial Right Now?Before you consider Capital One Financial, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capital One Financial wasn't on the list.

While Capital One Financial currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
2026-06-12 19:38 3mo ago
2026-05-08 09:45 4mo ago
Capital One Financial Has Five Preferreds For An Investor's Wallet
COF Capital One Financial
FMP Stock News
Original source text
Capital One Financial (COF) offers five series of preferred stocks, all rated BB, with yields around 6.6% and strong dividend coverage. COF's robust Tier 1 capital ratio and 19.8x equity-to-preferred coverage indicate minimal default or dividend risk for preferred holders. Net income covers preferred dividends by 10.3x, supporting income reliability even if net interest margins decline.
2026-06-12 19:38 3mo ago
2026-05-08 16:05 4mo ago
Capital One Announces Quarterly Dividend
COF Capital One Financial
FMP Stock News
Original source text
-

Company also declares preferred stock dividend

MCLEAN, Va.--(BUSINESS WIRE)--Capital One Financial Corporation (NYSE: COF) today announced a quarterly dividend of $0.80 per common share payable June 1, 2026, to stockholders of record at the close of business on May 19, 2026. The company has announced dividends on its common stock every quarter since it became an independent company on February 28, 1995. Dividends declared by the company are eligible for direct reinvestment in the company's common stock under its Dividend Reinvestment and Stock Purchase Plan. For additional Plan information, stockholders should contact Computershare Trust Company, N.A., at 1-888-985-2057 (inside the U.S. and Canada) or 1-781-575-2725 (outside the U.S. and Canada).

The company also declared a quarterly dividend on the outstanding shares of its 5.00 percent Fixed Rate Non-Cumulative Perpetual Preferred Stock, Series I (the "Series I Preferred Stock"). Each outstanding share of the Series I Preferred Stock is represented by depositary shares, each representing a 1/40th interest in a share of Series I Preferred Stock. The dividend of $12.50 per share (equivalent to $0.3125 per outstanding depositary share) will be paid on June 1, 2026, to stockholders of record at the close of business on May 19, 2026.

The company also declared a quarterly dividend on the outstanding shares of its 4.80 percent Fixed Rate Non-Cumulative Perpetual Preferred Stock, Series J (the "Series J Preferred Stock"). Each outstanding share of the Series J Preferred Stock is represented by depositary shares, each representing a 1/40th interest in a share of Series J Preferred Stock. The dividend of $12.00 per share (equivalent to $0.30 per outstanding depositary share) will be paid on June 1, 2026, to stockholders of record at the close of business on May 19, 2026.

The company also declared a quarterly dividend on the outstanding shares of its 4.625 percent Fixed Rate Non-Cumulative Perpetual Preferred Stock, Series K (the "Series K Preferred Stock"). Each outstanding share of the Series K Preferred Stock is represented by depositary shares, each representing a 1/40th interest in a share of Series K Preferred Stock. The dividend of $11.5625 per share (equivalent to $0.2890625 per outstanding depositary share) will be paid on June 1, 2026, to stockholders of record at the close of business on May 19, 2026.

The company also declared a quarterly dividend on the outstanding shares of its 4.375 percent Fixed Rate Non-Cumulative Perpetual Preferred Stock, Series L (the "Series L Preferred Stock"). Each outstanding share of the Series L Preferred Stock is represented by depositary shares, each representing a 1/40th interest in a share of Series L Preferred Stock. The dividend of $10.9375 per share (equivalent to $0.2734375 per outstanding depositary share) will be paid on June 1, 2026, to stockholders of record at the close of business on May 19, 2026.

The company also declared a quarterly dividend on the outstanding shares of its Fixed Rate Reset Non-Cumulative Perpetual Preferred Stock, Series M (the "Series M Preferred Stock"). The dividend of $9.875 per share will be paid on June 1, 2026, to stockholders of record at the close of business on May 19, 2026.

The company also declared a quarterly dividend on the outstanding shares of its 4.25 percent Fixed Rate Non-Cumulative Perpetual Preferred Stock, Series N (the "Series N Preferred Stock"). Each outstanding share of the Series N Preferred Stock is represented by depositary shares, each representing a 1/40th interest in a share of Series N Preferred Stock. The dividend of $10.625 per share (equivalent to $0.265625 per outstanding depositary share) will be paid on June 1, 2026, to stockholders of record at the close of business on May 19, 2026.

About Capital One

Capital One Financial Corporation (NYSE: COF) is a leading technology-based financial services company with $489.1 billion in deposits and $682.9 billion in total assets as of March 31, 2026. Headquartered in McLean, Virginia, the company operates as a premier global payments provider and diversified financial institution, delivering a broad suite of products and consumer lifestyle and shopping experiences through its Credit Card, Consumer Banking including its Global Payment Network, and Commercial Banking lines of business. As the only major U.S. bank to migrate entirely to the public cloud, Capital One leverages proprietary data and advanced analytics to democratize financial tools across its primary markets in the United States, Canada, and the United Kingdom.

More News From Capital One Financial Corporation

Back to Newsroom
2026-06-12 19:38 3mo ago
2026-05-09 08:00 4mo ago
Why one of the nation's largest auto lenders isn't worried about high vehicle prices or 'forever loans'
COF Capital One Financial
FMP Stock News
Original source text
The head of one of the nation's largest auto finance lenders isn't overly concerned about rising consumer automotive debt and inflated used car prices leading to longer loans on vehicle purchases.

His main reasoning? The percentage of income consumers are spending on their vehicles has remained relatively flat compared with 2019, before the coronavirus pandemic led to inflated pricing as demand surged but inventories stayed low.

"If I just told you, 'Car prices going up, interest rates going up, insurance prices going up,' you would say, 'You know what, consumers must be paying more as a ratio to the income,'" Capital One Auto President Sanjiv Yajnik told CNBC. "However, if you look at every quintile of salary and earnings of people, the payment-to-income ratio has remained fairly flat."

While Capital One reports median monthly car ownership payments have jumped from $390 to $525 since 2019, data provided exclusively to CNBC from its automotive unit suggest that vehicle costs have stayed relatively stable compared with income. That's because, overall, the payment-to-income ratio has remained flat at approximately 10% since 2019, according to the automotive arm of the American bank.

Capital One Auto found 80% of car purchasers who finance a vehicle are below the generally recognized payment to income threshold of 15%.

"The consumer is being cautious. They're being responsible. This is a much healthier way to do things than the alternative, because it's not a discretionary spend," said Yajnik, referring to consumers prioritizing vehicle payments for transportation, including work.

To get to that goal, however, more consumers are taking on longer loans to keep payments affordable.

The auto finance veteran's view contrasts with others in the industry who view the longer term loans as a detriment to consumers' pocketbooks.

They argue that so-called "forever loans" of six years or more have led to many buyers, particularly of new vehicles, being underwater on the equity of their cars and trucks. That means they owe more than their vehicle is worth when they decide to trade it in.

Edmunds reports roughly 26% of used vehicles purchased that involved a trade-in vehicle had negative equity this year through April. The amount of negative equity averaged $5,105, a 35% increase from 2019.

"As loan term lengths increase on average, the pace at which consumers make progress paying down their balance slows," Jessica Caldwell, head of insights for CarMax's Edmunds, wrote in a recent online post. "If consumers then trade in their vehicle too soon for any reason, they are increasingly left holding more loan debt."

Regarding financing for new vehicles during the first quarter, 90.2% of new vehicle loans involving trade-ins with negative equity carried terms of at least 72 months, and 43% extended to 84 months, according to Caldwell. The average negative equity trade-in was $7,183 during the quarter for new vehicles, according to Edmunds.

Those figures have been climbing since 2022, when inflated used vehicle values caused by a pandemic-fueled chip shortage insulated more shoppers from carrying debt into their next vehicle.

Consumers need to keep their vehicles for more time to make the long loans worth it, according to Yajnik. But that can also cause increases in maintenance costs as well as the likelihood that a vehicle needs repairs that exceed its value or has to be scrapped altogether.

"Yes, it takes longer to get your equity, but in the meantime, you get a use of the car, and you're earning money," said Yajnik, a 28-year veteran of Capital One who has led the automotive lending division since 2008.

The average listed price of a used vehicle was $25,390 in March, according to Cox's most recent data. That compares to new vehicles, which depreciate faster, at $48,667.

Cox Automotive reports if all other things are equal on a loan, financing for a $30,000 vehicle at a 9% annual percentage rate would cost $3,100 more on an 84-month term than a 48-month loan. However, there's a $264 difference in the monthly payments, which Yajnik said makes it more affordable for many consumers, especially those in lower income brackets.

"There's obviously going to be pockets that have problems, but one has to start from a different place, which is, for which reason are people buying cars, and are they doing so irrationally?" Yajnik said.
2026-06-12 19:38 3mo ago
2026-05-12 07:26 4mo ago
Is COF Undervalued? DCF Says Worth $320
COF Capital One Financial
FMP Stock News
Original source text
On May 12, 2026, we take a closer look at the discounted cash flow (DCF) analysis for Capital One Financial Corp COF . The stock has experienced a challenging price performance, with a year-to-date decline of 21.5%, although it has shown a slight increase of 1.4% over the past year.

DCF Earnings-based intrinsic value of $319.84 per share compared to the current price of $183.93, indicating a margin of safety of 42.5%. DCF Free Cash Flow (FCF)-based intrinsic value stands at $707.59, providing a second opinion on valuation. GF Score™ of 82/100 suggests a strong reliability of the DCF inputs, reflecting the company's overall financial health. What Is COF Worth? DCF Earnings-Based Model The DCF earnings-based model for Capital One Financial Corp utilizes a two-stage growth approach. In the first stage, we project earnings growth over the next ten years based on the current earnings per share (EPS) and the expected growth rate. In the second stage, we apply a terminal growth rate to estimate the value beyond the initial growth phase.

Parameter Value Current EPS (TTM, excl. non-recurring) $19.71 10-Year Growth Rate 10.2% 10-Year Treasury Rate 4.33% Discount Rate (ceil(Treasury) + 6%) 11% Terminal Growth Rate 4% In the first stage (Years 1-10), the EPS is expected to grow at a rate of 10.2% annually. This growth is then discounted at a rate of 11%, resulting in a growth stage value of $189.45 per share. In the second stage (Years 11-20), we apply a terminal growth rate of 4%, also discounted at 11%, yielding a terminal stage value of $130.39 per share.

Stage Description Value Growth Stage (Years 1-10) EPS growing at 10.2%, discounted at 11% $189.45 Terminal Stage (Years 11-20) 4% terminal growth, discounted at 11% $130.39 Intrinsic Value Growth + Terminal $319.84 With the current price at $183.93 compared to the intrinsic value of $319.84, Capital One Financial Corp is significantly undervalued, presenting a margin of safety of 42.5%. It is important to note that GuruFocus uses EPS excluding non-recurring items, as research indicates that stock prices correlate more closely with earnings than with free cash flow. For further analysis, you can visit the COF DCF Calculator.

What Does the Free Cash Flow DCF Say? The free cash flow (FCF)-based intrinsic value for Capital One Financial Corp is calculated at $707.59 per share. This figure provides a contrasting perspective to the earnings-based valuation. Both models indicate that the stock is significantly undervalued, with the FCF model showing an even larger margin of safety at 74.0%.

How Does GF Value™ Compare to the DCF Models? The GF Value™ for Capital One Financial Corp is calculated at $158.82, indicating that the stock is 15.8% overvalued based on this proprietary measure. GF Value™ is derived from historical trading multiples, past business growth, and future performance estimates. When comparing all three models, the DCF earnings and FCF models suggest significant undervaluation, while the GF Value™ presents a contrasting view of overvaluation. For more insights, visit the GF Value™ page.

What Does COF's GF Score™ Tell Us? The GF Score™ ranks stocks from 0 to 100 based on five key aspects: Financial Strength, Profitability, Growth, Valuation, and Momentum. Stocks with higher GF Score™ values have historically generated higher long-term returns (backtested from 2006 to 2021).

Metric Rating GF Score™ 82/100 Financial Strength 4/10 Profitability 6/10 Growth 9/10 Valuation 6/10 Momentum 5/10 With a predictability rank of 2/5 stars, the reliability of the DCF model for Capital One Financial Corp is moderate, suggesting that investors should exercise caution when interpreting the DCF results. For more information, visit the COF stock page.

Key Assumptions and Limitations It is essential to note that DCF models are highly sensitive to the assumptions made regarding growth rates and discount rates. Additionally, stocks with low predictability ratings, such as Capital One Financial Corp's 2/5 stars, tend to produce less reliable DCF estimates. The terminal growth rate of 4% is a simplifying assumption that may not reflect future economic conditions.

What This Means for Investors In summary, the analysis of Capital One Financial Corp through the DCF earnings model, the DCF FCF model, and the GF Value™ perspective reveals a complex picture. While the DCF models indicate that the stock is significantly undervalued, the GF Value™ suggests a different viewpoint of overvaluation. Overall, the consensus leans towards undervaluation based on the DCF metrics. For the full DCF analysis, visit the COF DCF Calculator. You can also explore the GF Value™ page, or use the GuruFocus Stock Screener to find undervalued predictable companies.

Frequently Asked Questions What is COF's intrinsic value based on DCF?

[Answer: earnings-based $319.85, FCF-based $707.59]

Is COF overvalued or undervalued?

[Answer using DCF + GF Value™ consensus]

How reliable is the DCF model for COF?

[Answer using predictability rank 2/5]

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
2026-06-12 19:38 3mo ago
2026-05-17 14:43 3mo ago
I earn thousands yearly from credit card rewards: should I count them as income in my budget?
COF Capital One Financial
FMP Stock News
Original source text
© Pormezz / Shutterstock.com

A listener named Suzanne from Austin wrote into the How to Money podcast with a question I think a lot of points-and-miles people quietly wrestle with: she earns “several thousand dollars every year” from cashback cards, signup bonuses, drugstore and grocery store points, and loyalty programs. She views the haul as “windfalls earned through organic spending” but admits the “combined monetary influx seems significant from a budgetary standpoint.” So should she pencil it into her monthly budget as income?

The hosts gave a clean answer, and I agree with it: track your rewards obsessively, but do not budget them as income. Those are two different jobs. Conflating them is how people end up spending more than they earn while feeling like savvy optimizers.

The verdict: rewards are a rebate on spending you already did A credit card reward is a discount on money you already spent. It works differently from a side hustle or a dividend payment, which generate new income. A paycheck arrives whether or not you go shopping. Rewards only show up because you went shopping. Treating them as income flips the causality and quietly nudges you to spend more to “earn” more, which is exactly backward.

Here is the trap in plain numbers. One of the hosts mentioned earning a $1,000 bonus on Capital One (NYSE:COF | COF Price Prediction)’s Business Spark Cash Card by spending $10,000 on his coffee bar project, including an expensive Italian espresso machine. That is a real reward on real spending he was going to do anyway. The bonus functioned as a 10% rebate on a planned purchase. Perfect use of a card.

Now imagine the inverse. You see a 2% cashback promo and tell yourself you will “earn” $2 back on a $100 purchase. If you did not need the $100 item, you just wasted $98 to earn $2. The math does not become friendlier as the numbers scale. 2% back on a $1,000 impulse buy is $980 you set on fire. Once rewards become a line item you are trying to hit, manufactured spending is the inevitable next step.

The macro backdrop makes this more urgent. The U.S. personal savings rate sits at 4% in the first quarter of 2026, down from 6% in early 2024. Households are already spending a higher share of their disposable income than they were two years ago. Wiring rewards into the budget as income gives you psychological permission to spend even more.

The variable that decides whether a card earns its keep The variable is the annual fee, and the tracking habit is what tells you whether you are winning or losing on it. One host walked through a clean example: he dropped his American Express (NYSE:AXP) Blue Cash Preferred card after realizing he could not overcome the $95 annual fee since he was shopping more at Costco (NASDAQ:COST). Without tracking, that fee would have just kept renewing in the background.

Run the math on any fee card. If a card charges $95 a year and offers 6% back on groceries up to $6,000, you need to run enough qualifying grocery spend through it to clear the fee before the rewards start working for you. Below that threshold, the rewards-as-income illusion is masking a net loss. Above it, the card is genuinely paying you. Many card backends automatically track your earnings (Fidelity and Costco cards both do this), so the tracking work is often already done for you.

I have been optimizing cards for years now, and the cards I keep are the ones I can defend on a spreadsheet. The ones I cancel are the ones where I caught myself rationalizing the fee.

What to do this week Three concrete actions:

Tally last year’s rewards per card. Most issuers show a year-end summary. Subtract any annual fee. If the net number is negative or barely positive, the card is a candidate for cancellation or a product change to a no-fee version. Keep rewards out of your income column. Park them in a separate sinking fund labeled travel, holiday gifts, or a brokerage deposit. The hosts call rewards “semi-volatile” and note that many come as hotel and flight points rather than literal cash, which makes them unreliable as monthly income anyway. Apply the $98 test before any purchase. Ask whether you would buy this item if the card offered zero rewards. If the answer is no, the rebate is just making you poorer more slowly than paying cash would. Rewards are icing. Budgets are the cake. Confuse the two and you end up with a lot of icing and no cake.
2026-06-12 19:38 3mo ago
2026-05-25 17:15 3mo ago
Discover Credit Cards Are About to Become Capital One Cards. Why That Could Be a Bigger Deal Than Investors Think.
COF Capital One Financial
FMP Stock News
Original source text
Capital One Financial (COF +1.15%) dramatically changed its business model by acquiring payment processor Discover. The big benefit of the deal is the more consistent revenue provided by payment processing, but there are other positives, too. For example, capitalizing on operating synergies in the card business will begin in July.

Capital One is basically cutting costs Processing payments is a revenue story, and an important one. Collecting small fees every time a retailer processes a transaction generates consistent income for Capital One. That will provide a more reliable foundation for the business, which tends to focus on lending to higher-risk customers. This could be an important ballast for the business during recessions. But buying Discover isn't just about revenue; it's also about costs.

Image source: Getty Images.

Discover processes payments, but it also issues credit cards. Capital One, which has its own credit cards, doesn't want to manage two separate credit card businesses because many functions will be redundant. That said, managing a financial services business is complex, and big mistakes aren't an option. The financial services giant can't rush the card integration effort.

Starting in July 2026, Capital One will start migrating Discover cards to its own back-office platform. The methodical migration of Discover's card portfolio is expected to take until early 2027. The benefits Discover cardholders currently have shouldn't change dramatically, but they will be required to set up accounts with Capital One. That is the largest customer impact in the move, and it is a material one since consumers often avoid change when it comes to financial relationships.

Capital One has a big target Capital One's goal is to generate up to $2.7 billion in synergies. Roughly $1.5 billion of that will come from savings generated by the back office migration of Discover's credit card business. The full benefit of these savings won't show up until the second half of 2027, assuming everything goes according to plan. The goal is to eliminate 25% of Discover's operating expenses and 10% of its marketing expenses. Those savings will help improve profitability for the combined business.

Today's Change

(

1.15

%) $

2.09

Current Price

$

184.13

Another $1.2 billion or so in synergies is expected to come from the revenue side, and those benefits are already showing through. Capital One has migrated some Capital One transactions to the Discover payment network. At this point, the plan is to hit at least $2.5 billion in synergies from cost-cutting and revenue enhancement by mid-2027.

The behind-the-scenes work matters The truth is that most of the work happening right now on the integration of Discover will be largely invisible to the outside world. However, it requires significant internal work at Capital One. But the payoff could be huge, with management targeting a roughly 15% boost to adjusted earnings in 2027. Although Capital One's stock is down 20% so far in 2026, shareholders will likely be pleased with the progress the company is making in its integration.
2026-06-12 19:38 3mo ago
2026-05-31 12:15 3mo ago
Capital One's Auto Loan Trends Are Quietly Improving. Why It Matters for the Stock.
COF Capital One Financial
FMP Stock News
Original source text
Capital One (COF +1.15%) is changing its business model in a significant way following its acquisition of Discover. The key shift is that it will now issue credit cards and process credit card transactions, which generates reliable fee income. Other than that, the company's core focus on lending to lower-credit-quality customers remains in place. But as this big business shift is underway, Capital One's auto lending trends are surprisingly positive news.

Capital One: High risk and high reward Lower-credit-quality customers are willing to pay higher interest rates for access to debt. That is true with both credit cards, which are effectively revolving credit facilities, and with car loans, which are longer-term asset-backed loans. Auto loans have a history of being particularly risky during recessions, when customers' finances are stretched.

Image source: Getty Images.

Since a large chunk of money is already out the door, the only option to recoup losses is to repossess the car. That is not an easy or pleasant experience for anyone involved, since the repossessed car will need to be resold to extract any value it may have. Credit card balances generally aren't as large as those for a car loan, so individually they don't pose the same risk.

Watching Capital One's car loans Essentially, Capital One's car loans can serve as an important leading indicator of credit risk. This is why the business, while smaller than its credit card operation, is worth watching very closely. Right now, the risk doesn't seem all that high, even though consumers are tightening their budgets amid rising inflation. And the fact that high oil prices have some on Wall Street worried about a global recession.

Today's Change

(

1.15

%) $

2.09

Current Price

$

184.13

In the first quarter of 2026, auto charge-offs fell 18 basis points from the fourth quarter of 2025. While they were up nine basis points year over year, they were still a fairly reasonable 1.64%. In April, the figure was even better at 1.2%. So even when there is a problem with an auto loan, the company is managing to recoup much of its loss. Non-performing auto loans, meanwhile, amounted to just 0.55% of its loan book, down from the fourth quarter and the year-ago period. That figure held steady in April.

All in, Capital One's auto loan portfolio isn't screaming that the bank's credit risks are rising. That's a positive sign for investors, but one that you should continue to monitor. When the economy turns south, which it will eventually do at some point, the bank's auto loans could be where the impact starts to hit first. A good indicator of that risk would likely show up first in the 30-day delinquency rates, but those were down sequentially and year over year for auto loans in the first quarter, as well, with an even further decline in the Month of April.
2026-06-12 19:38 3mo ago
2026-06-01 10:48 3mo ago
Capital One Software Announces New Observability and AI-Powered Optimization Capabilities for Slingshot to Drive System-Wide Data Efficiency
COF Capital One Financial
FMP Stock News
Original source text
-

Context-Driven Insights Improve Snowflake Performance, Detect and Resolve Data Infrastructure Issues

MCLEAN, Va.--(BUSINESS WIRE)--Capital One Software, the enterprise B2B software business of Capital One, today announced intelligent optimization features for Capital One Slingshot, designed to improve performance and quickly detect and resolve data infrastructure issues. By utilizing context across a user's environment, Slingshot will identify opportunities to improve workload performance in Snowflake that go beyond basic SQL syntax and storage costs.

These features reflect a fundamental shift in how enterprises can approach data efficiency: not just tuning individual resources in isolation, but understanding and optimizing the entire system, including code, pipelines, infrastructure and the teams running them.

“Enterprise data infrastructure is a complex web of inter-dependencies that requires a context-first approach for optimization at scale,” said Jeff Chou, VP, Slingshot Product Management, Capital One Software. "Slingshot’s intelligent optimization capabilities can help businesses understand what their queries are actually doing, what their tables are built for, and where their teams are unknowingly duplicating work. That's how we help enterprises get efficient at the system level.”

Upcoming Slingshot features include:

Context-Aware AI Query Optimization: Enterprise Snowflake environments generate staggering query volumes that no team can manually evaluate at scale. Slingshot will automatically identify top queries by cost, runtime, and frequency in Snowflake environments. It will generate AI-powered optimization recommendations that surface clear, actionable steps and project cost and runtime improvements for both Snowflake admins and data engineers. Context-Aware AI Table Optimization: Query inefficiency often doesn’t stem from the query itself, but from poorly configured tables. Slingshot’s Table Optimization capability will analyze the top 50 tables by query impact and surface multi-dimensional infrastructure fixes. Slingshot will also validate that proposed table changes will not negatively impact the top queries already running against that table, before surfacing the recommendation. Duplicate Pipeline Detection: Large enterprises have full pipelines that are unknowingly redundant. Slingshot's AI-powered duplicate pipeline detection will identify these redundancies by looking at common patterns of data usage to find potential overlap. Slingshot uses AI to compare many potentially-similar workloads to evaluate functional equivalence. Data Explorer: This interactive, drill-down analytics interface will allow data teams to investigate root causes. Users can interactively slice Snowflake costs across various dimensions (accounts, users, query hashes, Slingshot tags, service types) with synchronized filtering. Drill-downs offer rich object detail pages for individual warehouses, databases, and queries, collapsing the gap between cost visibility and actionable change. Data rich before-and-after impact analysis pages provide historical context for any changes made to a Warehouse. Learn more about the latest Slingshot innovations by visiting Capital One Software at these upcoming events:

Booth #1211 at Snowflake Summit, June 1-4, 2026 in San Francisco, CA Booth #223 at Gartner Security and Risk Management Summit, June 1-3, 2026 in National Harbor, MD About Capital One Software
Capital One Software, the enterprise B2B software business of Capital One, enables organizations to scale their data management capabilities and better harness the power of AI. Backed by 25 years of data innovation, Capital One Software solutions are helping customers overcome key data management challenges in the cloud, including cost performance, infrastructure management, and data security. Capital One Software is based in McLean, Virginia, at Capital One's headquarters. To learn more, go to: www.capitalone.com/software

About Capital One
Capital One Financial Corporation (NYSE: COF) is a leading technology-based financial services company with $475.8 billion in deposits and $669.0 billion in total assets as of December 31, 2025. Headquartered in McLean, Virginia, the company operates as a premier global payments provider and diversified financial institution, delivering a broad suite of products and consumer lifestyle and shopping experiences through its Credit Card, Consumer Banking including its Global Payment Network, and Commercial Banking lines of business. As the only major U.S. bank to migrate entirely to the public cloud, Capital One leverages proprietary data and advanced analytics to democratize financial tools across its primary markets in the United States, Canada, and the United Kingdom.

Forward-Looking Statements
This press release contains forward-looking statements regarding Capital One Software’s strategy and future product features. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially. Factors such as technical challenges, market shifts, or changes in resource allocation may result in some features being delayed, modified, or not released at all. Capital One Software assumes no obligation to update these forward-looking statements as circumstances change.

More News From Capital One Software

Back to Newsroom
2026-06-12 19:38 3mo ago
2026-06-01 11:00 3mo ago
Capital One Software Announces New Observability and AI-Powered Optimization Capabilities for Slingshot to Drive System-Wide Data Efficiency
COF Capital One Financial
FMP Stock News
Original source text
Capital One Software Announces New Observability and AI-Powered Optimization Capabilities for Slingshot to Drive System-Wide Data Efficiency Capital One Software, the enterprise B2B software business of Capital One, today announced intelligent optimization features for Capital One Slingshot, designed to improve performance and quickly detect and resolve data infrastructure issues. By utilizing context across a user's environment, Slingshot will identify opportunities to improve workload performance in Snowflake that go beyond basic SQL syntax and storage costs.

These features reflect a fundamental shift in how enterprises can approach data efficiency: not just tuning individual resources in isolation, but understanding and optimizing the entire system, including code, pipelines, infrastructure and the teams running them.

“Enterprise data infrastructure is a complex web of inter-dependencies that requires a context-first approach for optimization at scale,” said Jeff Chou, VP, Slingshot Product Management, Capital One Software. "Slingshot’s intelligent optimization capabilities can help businesses understand what their queries are actually doing, what their tables are built for, and where their teams are unknowingly duplicating work. That's how we help enterprises get efficient at the system level.”

Upcoming Slingshot features include:

Context-Aware AI Query Optimization: Enterprise Snowflake environments generate staggering query volumes that no team can manually evaluate at scale. Slingshot will automatically identify top queries by cost, runtime, and frequency in Snowflake environments. It will generate AI-powered optimization recommendations that surface clear, actionable steps and project cost and runtime improvements for both Snowflake admins and data engineers. Context-Aware AI Table Optimization: Query inefficiency often doesn’t stem from the query itself, but from poorly configured tables. Slingshot’s Table Optimization capability will analyze the top 50 tables by query impact and surface multi-dimensional infrastructure fixes. Slingshot will also validate that proposed table changes will not negatively impact the top queries already running against that table, before surfacing the recommendation. Duplicate Pipeline Detection: Large enterprises have full pipelines that are unknowingly redundant. Slingshot's AI-powered duplicate pipeline detection will identify these redundancies by looking at common patterns of data usage to find potential overlap. Slingshot uses AI to compare many potentially-similar workloads to evaluate functional equivalence. Data Explorer: This interactive, drill-down analytics interface will allow data teams to investigate root causes. Users can interactively slice Snowflake costs across various dimensions (accounts, users, query hashes, Slingshot tags, service types) with synchronized filtering. Drill-downs offer rich object detail pages for individual warehouses, databases, and queries, collapsing the gap between cost visibility and actionable change. Data rich before-and-after impact analysis pages provide historical context for any changes made to a Warehouse. Learn more about the latest Slingshot innovations by visiting Capital One Software at these upcoming events:

Booth #1211 at Snowflake Summit, June 1-4, 2026 in San Francisco, CA Booth #223 at Gartner Security and Risk Management Summit, June 1-3, 2026 in National Harbor, MD About Capital One Software
Capital One Software, the enterprise B2B software business of Capital One, enables organizations to scale their data management capabilities and better harness the power of AI. Backed by 25 years of data innovation, Capital One Software solutions are helping customers overcome key data management challenges in the cloud, including cost performance, infrastructure management, and data security. Capital One Software is based in McLean, Virginia, at Capital One's headquarters. To learn more, go to: www.capitalone.com/software

About Capital One
Capital One Financial Corporation (NYSE: COF) is a leading technology-based financial services company with $475.8 billion in deposits and $669.0 billion in total assets as of December 31, 2025. Headquartered in McLean, Virginia, the company operates as a premier global payments provider and diversified financial institution, delivering a broad suite of products and consumer lifestyle and shopping experiences through its Credit Card, Consumer Banking including its Global Payment Network, and Commercial Banking lines of business. As the only major U.S. bank to migrate entirely to the public cloud, Capital One leverages proprietary data and advanced analytics to democratize financial tools across its primary markets in the United States, Canada, and the United Kingdom.

Forward-Looking Statements
This press release contains forward-looking statements regarding Capital One Software’s strategy and future product features. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially. Factors such as technical challenges, market shifts, or changes in resource allocation may result in some features being delayed, modified, or not released at all. Capital One Software assumes no obligation to update these forward-looking statements as circumstances change.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260601466677/en/
2026-06-12 19:38 3mo ago
2026-06-02 07:12 3mo ago
Is COF Undervalued? DCF Says Worth $320
COF Capital One Financial
FMP Stock News
Original source text
On June 02, 2026, we delve into the DCF analysis for Capital One Financial Corp COF , a company currently facing a challenging market environment with a year-to-date decline of 23.2%. The stock's recent performance has raised questions about its valuation and future growth potential.

DCF Earnings-based intrinsic value of $319.84 vs current price of $184.56 (margin of safety: 42.3%) DCF FCF-based intrinsic value of $707.59 vs current price (second opinion: significantly undervalued with 73.9% margin of safety) GF Score™ of 80/100 indicates strong reliability of the DCF inputs What Is COF Worth? DCF Earnings-Based Model The DCF earnings-based model for Capital One Financial Corp utilizes a two-stage growth approach. In the first stage, we project the company's earnings growth over the next ten years based on a growth rate of 10.2%. This growth is then discounted at a rate of 11%, which reflects the risk-free rate and equity risk premium. In the second stage, we apply a terminal growth rate of 4% for the subsequent ten years, also discounted at 11%. The following table summarizes the key assumptions used in this model:

Parameter Value Current EPS (TTM, excl. non-recurring) $19.71 10-Year Growth Rate 10.2% 10-Year Treasury Rate 4.43% Discount Rate (ceil(Treasury) + 6%) 11% Terminal Growth Rate 4% The calculation summary for the DCF earnings-based model is as follows:

Stage Description Value Growth Stage (Years 1-10) EPS growing at 10.2%, discounted at 11% $189.45 Terminal Stage (Years 11-20) 4% terminal growth, discounted at 11% $130.39 Intrinsic Value Growth + Terminal $319.84 With the current price at $184.56 compared to the intrinsic value of $319.84, the stock appears significantly undervalued, presenting a margin of safety of 42.3%. It is important to note that GuruFocus uses EPS without non-recurring items in its calculations, as research indicates that stock prices correlate more closely with earnings than with free cash flow. For further analysis, you can visit the COF DCF Calculator.

What Does the Free Cash Flow DCF Say? In addition to the earnings-based DCF model, we also consider the free cash flow (FCF) DCF model, which yields an intrinsic value of $707.59. This significantly higher valuation compared to the earnings-based model reinforces the conclusion that Capital One Financial Corp is undervalued, with a substantial margin of safety of 73.9%. The agreement between the two models suggests a strong underlying value for the company.

How Does GF Value™ Compare to the DCF Models? The GF Value™ for Capital One Financial Corp is calculated at $161.57, indicating that the stock is currently overvalued based on this proprietary measure. GF Value™ is derived from historical trading multiples, past business growth, and future performance estimates. While the DCF models suggest significant undervaluation, the GF Value™ presents a contrasting view, highlighting the importance of considering multiple valuation perspectives. For more details, visit the GF Value™ page.

What Does COF's GF Score™ Tell Us? The GF Score™ ranks stocks from 0 to 100 based on five key aspects: Financial Strength, Profitability, Growth, Valuation, and Momentum. Stocks with higher GF Score™ values have been shown to generate higher long-term returns based on backtested data from 2006 to 2021. The following table outlines COF's GF Score™ metrics:

Metric Rating GF Score™ 80/100 Financial Strength 4/10 Profitability 6/10 Growth 9/10 Valuation 6/10 Momentum 5/10 With a predictability rank of 2 out of 5 stars, it is essential to note that higher predictability ratings generally lead to more reliable DCF estimates for stocks. For further insights, you can explore the COF stock page.

Key Assumptions and Limitations It is crucial to recognize that DCF models are highly sensitive to the assumptions made regarding growth rates and discount rates. Stocks with lower predictability ratings, such as COF's 2 out of 5 stars, tend to produce less reliable DCF estimates. Additionally, the terminal growth rate of 4% used in this analysis is a simplifying assumption that may not fully capture the complexities of future growth.

What This Means for Investors In synthesizing the results from the three valuation models—DCF earnings, DCF FCF, and GF Value™—we find a mixed picture for Capital One Financial Corp. While the DCF models indicate significant undervaluation, the GF Value™ suggests a different perspective, highlighting potential overvaluation. Overall, the consensus leans towards undervaluation based on the DCF models, but investors should consider the varying insights from all three approaches. For the full DCF analysis, visit the COF DCF Calculator. You can also explore the GF Value™ page, or use the GuruFocus Stock Screener to find undervalued predictable companies.

Frequently Asked Questions What is COF's intrinsic value based on DCF?

Answer: earnings-based $319.85, FCF-based $707.59

Is COF overvalued or undervalued?

Answer: The DCF models suggest undervaluation, while GF Value™ indicates overvaluation.

How reliable is the DCF model for COF?

Answer: The predictability rank is 2/5, indicating less reliability in the DCF estimates.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
2026-06-12 19:37 3mo ago
2026-06-09 16:32 3mo ago
Capital One Financial Corporation (COF) Presents at Morgan Stanley US Financials Conference 2026 Transcript
COF Capital One Financial
FMP Stock News
Original source text
Capital One Financial Corporation (COF) Presents at Morgan Stanley US Financials Conference 2026 Transcript
2026-06-12 19:37 3mo ago
2026-06-11 12:54 3mo ago
Trump Picks Capital One Exec Brian Johnson to Lead CFPB
COF Capital One Financial
FMP Stock News
Original source text
The Consumer Financial Protection Bureau (CFPB) may be getting a new leader. President Donald Trump nominated former CFPB deputy director and current Capital One executive Brian Johnson to a five-year term as director of the agency.
2026-06-12 19:37 3mo ago
2026-05-11 20:42 4mo ago
Expedia Group Inc (EXPE) Shares Fall 3.6% -- GF Value Says Still Overvalued
EXPE Expedia
FMP Stock News
Original source text
On May 11, 2026, Expedia Group Inc EXPE shares fell 3.6% to a current price of $221.46. This decline adds to a challenging year for the stock, which has experienced a year-to-date drop of 21.7% and traded within a 52-week range of $148.55 to $303.80.

GF Value™ verdict: Current price is $221.46 vs GF Value™ of $202.26, indicating the stock is 9.5% overvalued.GF Score™: 87/100, suggesting strong overall performance.Notable signal: Insiders sold $1.8 million in the last three months, indicating potential caution among company executives. Is EXPE Overvalued or Undervalued? The current price of Expedia Group Inc EXPE at $221.46 is above the GF Value™ estimate of $202.26, which categorizes the stock as 9.5% overvalued. This overvaluation presents a risk for potential investors as the price may not adequately reflect the company's intrinsic value. The GF Valuation label indicates that the stock is fairly valued, which means that while it may not be a bargain, it is also not significantly overpriced based on the company's fundamentals. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.

Investors should be cautious given the overvaluation signal, as it suggests that the stock may not provide sufficient margin of safety for new buyers. A significant correction could occur if market conditions change or if the company fails to meet growth expectations. In contrast, if the stock were undervalued, it could present an opportunity for long-term gains, but such a scenario is not currently applicable to EXPE.

How Does EXPE's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 19.5x 24.6x Forward P/E 11.5x N/A Currently, EXPE's P/E (TTM) of 19.5x is significantly below its 5-year median P/E of 24.6x, indicating that the stock is trading at a discount relative to its historical valuation. The forward P/E of 11.5x further highlights this disparity. This P/E analysis aligns with the GF Value™ verdict of overvaluation, suggesting that even though EXPE might appear cheaper relative to its past, it is still above the GF Value™ estimate and may not present a compelling buying opportunity at this time.

What Does EXPE's GF Score™ Tell Us? Metric Rating GF Score™ 87 Financial Strength 5/10 Profitability 8/10 Growth 8/10 Valuation 6/10 Momentum 8/10 The GF Score™ of 87/100 indicates that Expedia Group Inc has strong overall performance potential. The strongest areas are in profitability and growth, both rated at 8/10, suggesting that the company has been able to maintain healthy margins and show promising growth prospects. However, financial strength is a concern, rated only 5/10, which may indicate vulnerabilities in its balance sheet or capital structure. This mixed picture highlights the need for caution among potential investors despite the overall high GF Score™.

What Are Insiders Doing with EXPE Stock? In the last three months, insiders at Expedia Group Inc have sold approximately $1.8 million worth of shares with no recorded buying activity. This trend of selling could suggest a lack of confidence among executives regarding the company’s short-term outlook or valuation. When insiders sell shares, it can often signal that they believe the stock price may not appreciate in the near future, which warrants attention from potential investors.

What This Means for Investors Based on the current valuation metrics and the GF Value™ estimate, Expedia Group Inc EXPE is overvalued at this time. The price is trading above the intrinsic value calculated by GF Value™, indicating potential risks for investors looking to enter the stock.

For the complete analysis, visit the Expedia Group Inc EXPE stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is EXPE's GF Score™?

EXPE's GF Score™ is 87/100, indicating strong overall performance potential based on multiple financial metrics.

Is EXPE overvalued or undervalued?

EXPE is currently overvalued, as its stock price of $221.46 is above the GF Value™ estimate of $202.26.

What is EXPE's P/E ratio?

EXPE's P/E (TTM) is 19.5x, which is significantly lower than its 5-year median P/E of 24.6x, indicating it is trading at a discount relative to its historical valuation.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
2026-06-12 19:37 3mo ago
2026-05-13 16:01 4mo ago
Expedia Group to Webcast Explore 26 General Opening Session on May 19, 2026
EXPE Expedia
FMP Stock News
Original source text
-

SEATTLE--(BUSINESS WIRE)--Expedia Group (NASDAQ: EXPE) will webcast the general opening session of Explore 26, on May 19, 2026, at 2:00 p.m. PT. Explore 26 is Expedia Group’s annual partner event where the company will share new innovations focused on improving the complete travel experience for travelers and partners everywhere.

The webcast will be available on the Investor Relations website; ir.expediagroup.com.

Expedia GroupNASDAQ:EXPE

Release Versions

More News From Expedia Group

Expedia Group to Participate in Evercore’s 2026 Global TMT ConferenceSEATTLE--(BUSINESS WIRE)--Expedia Group (NASDAQ: EXPE) will participate in Evercore’s 2026 Global TMT Conference. Ariane Gorin, Chief Executive Officer, will participate in a fireside chat on Tuesday, June 2, 2026 at 10:00 am PT / 1:00 pm ET. A live webcast of the session will be available at ir.expediagroup.com. A replay of the webcast will be accessible for 3 months. About Expedia Group Expedia Group, Inc. (NASDAQ: EXPE) is the global travel marketplace with one purpose: to help travelers exp...

Expedia Group Reports First Quarter 2026 ResultsSEATTLE--(BUSINESS WIRE)--Expedia Group, Inc. (NASDAQ: EXPE) announced financial results today for the first quarter ended March 31, 2026. First Quarter Highlights (All comparisons year-over-year) Booked room nights grew 6%. Total gross bookings grew 13%, while B2B gross bookings grew 22% and B2C grew gross bookings 10%. Lodging gross bookings grew 13%. Revenue grew 15%, driven by B2B, which grew 25%. GAAP net loss decreased 97% while Adjusted net income grew 361%. Adjusted EBITDA increased 83%...

Expedia Group Appoints Derek Andersen as Chief Financial OfficerSEATTLE--(BUSINESS WIRE)--Expedia Group, Inc. (Nasdaq: EXPE) today announced that Derek Andersen has been appointed Chief Financial Officer, effective May 11, 2026. As CFO, Mr. Andersen will lead Expedia Group’s global finance organization and report to Chief Executive Officer Ariane Gorin. He succeeds Scott Schenkel, who is stepping down from the role of CFO after strengthening the company’s financial foundation and supporting margin expansion over the last 16 months. Mr. Schenkel will stay on...

Back to Newsroom
2026-06-12 19:37 3mo ago
2026-05-19 17:15 3mo ago
Expedia at 30, the inside story: Online travel giant navigates its third tech disruption
EXPE Expedia
FMP Stock News
Original source text
From left: Expedia Group chairman Barry Diller, CEO Ariane Gorin, former CEO and current Uber CEO Dara Khosrowshahi, and founder Rich Barton at Expedia’s Explore partner conference in Las Vegas this week. (Expedia Group Photo) From her office overlooking the atrium at Expedia Group’s sunlit headquarters campus on the Seattle waterfront, CEO Ariane Gorin puts the online travel giant’s 30-year history into three chapters, each tied to a major inflection point in the evolution of technology.

Chapter 1 was the internet itself: the 1996 launch of Expedia inside Microsoft, when a small team bet that consumers could benefit from technology previously exclusive to travel agents.

Chapter 2 was mobile: as travelers migrated from desktop to smartphone, Expedia rebuilt itself for the small screen and assembled a collection of brands through a wave of acquisitions. 

Chapter 3, Gorin says, is artificial intelligence, and it’s only starting to unfold. Expedia is now positioning itself for a new reality in which different types of agents — machines, not humans — will play a role in booking travel, in some cases making the decisions entirely on their own.

“It’s exciting to get to write the future of AI and travel,” Gorin said.

Expedia is marking its 30th year in business this week with the launch of the Expedia Trails Fund, a philanthropic initiative to restore outdoor trails across the U.S., backed by an initial $4.3 million in grants. 

The company is also bringing top executives from throughout its history — founder Rich Barton, chairman Barry Diller, and former CEO Dara Khosrowshahi — together with Gorin for its partner conference in Las Vegas. Collectively, they grew Expedia from internal division to corporate spinout to online travel giant. 

What happens next, under Gorin, will depend on Expedia’s ability to reinvent itself for a fundamentally new relationship between travelers and technology — attempting to continue a pattern that has repeated itself throughout the company’s history.

Chapter 1: ‘Power to the people’ Expedia started with a question: why shouldn’t everyone see what travel agents do? 

In 1994, Rich Barton was a 27-year-old Microsoft employee, working on a CD-ROM travel guidebook — an Encarta for travel — when he learned about the airline reservation systems that travel agents used to book flights. The systems were accessible electronically, but only to industry insiders. He started to imagine regular people using them directly.

Rich Barton speaks at Seattle University’s Albers Executive Speaker Series in 2016. (GeekWire Photo / Kevin Lisota) “The idea was simple and almost obvious once you said it out loud: give consumers the same information the professionals have, and get out of their way,” recalled Barton, now a well-known entrepreneur and investor, who shared new details of the Expedia story for this piece. 

His term for this approach would ultimately define his career: “Power to the People.”

Barton pitched the idea directly to Microsoft CEO Bill Gates and President Steve Ballmer, who gave him the green light.

Secretly building for the web The team initially started building the product for Microsoft’s proprietary online service, MSN 1.0, a would-be competitor to AOL, which had a proprietary multimedia development environment called Blackbird. Then the web gained steam, with its open protocols and universal reach. 

That’s when Greg Slyngstad, the original general manager of what was then called Microsoft Travel, made a pivotal call: develop the product for the open web instead of Microsoft’s walled garden. 

Slyngstad “knew the web would win,” Barton said. “Because of this, we secretly built for the web, which was brilliant. Expedia would not be what it is today if not for that decision.” 

An early version of Expedia from the Internet Archive. Before it was called Expedia, the project had a very different interface. In the early days of Microsoft Travel, the hot trend in software was the social user interface, personified most memorably by the widely mocked Microsoft Bob. Barton’s team had its own version: a parrot that served as a travel planning guide.

“I can’t remember the name of the parrot now,” he said, “but I faked a travel planning scenario talking to a robot parrot in front of the whole Consumer Division — which was a hit!”

‘We had massive ambition’ A plaque still on the Microsoft campus in Redmond marks what came next: “Microsoft Expedia, Version 1.0, Shipped October 22, 1996.”

A marker commemorating the Expedia launch in a courtyard at Microsoft. (GeekWire Photo / Todd Bishop) Microsoft’s annual report for 1997 described Expedia as “a free travel service on the World Wide Web and MSN which enables users to find low fares, book flights, make hotel reservations, and rent cars.”

Barton and team had a much bigger vision. “We had massive ambition,” he said. Their BHAG — or “big, hairy, audacious goal,” the term popularized by author Jim Collins around the same time — was to become “the largest seller of travel in the world.”

Expedia’s revenue went from zero to $38.7 million by 1999. At the time, it was still about half the size of Travelocity, which had gotten to market first. 

‘Go do this on your own!’ But Barton was already seeing a future for Expedia outside the software giant. 

“One of my core arguments was that Expedia, in success, would become a travel company first and a tech company second,” he explained. “Therefore, we simply wouldn’t fit inside a giant tech company, and that by setting us free, it would dramatically improve our chances of fulfilling our giant global dreams.”

So Barton made the case to Ballmer, his boss at the time, to let him and his team of “internet adventurers” spin out through an initial public offering, with Microsoft retaining a stake.

He pasted a printout of Ballmer’s headshot onto an IATA card, the credential issued by the International Air Transport Association to licensed travel agents. “Steve, do you want to be a travel agent?” Barton remembers asking. “Do you want to run the largest travel agency in the world?”

Ballmer recoiled at the idea and yelled, “No, you guys should go do this on your own!” Then he asked if he could keep the card.

And with that, the spinout was set in motion.

The IPO prospectus in September 1999 described Expedia’s value proposition: “one-stop travel shopping and reservation services, providing reliable, real-time access to schedule, pricing and availability information.” Travel, it said, was uniquely suited to the internet: a global market with millions of buyers, and purchases “involving large amounts of information from multiple sources.”

‘Whoops and hollers’ Expedia went public on Nov. 10, 1999. The company had 138 employees. The stock, initially priced at $14 a share, soared more than 260% on its first day of trading. 

“We’re feelin’ pretty good,” said Suzi Levine, who led Expedia’s IPO communications, in a Seattle Post-Intelligencer story about the Nasdaq debut, admitting “there may have been one or two whoops and hollers” around the office. Levine went on to become the U.S. Ambassador to Switzerland under President Obama, among other high-profile government positions. 

Another newspaper clipping from that week shows Barton and his wife Sarah holding their newborn son William, born the same day as the IPO. The headline: “Initial public offspring.”

Rich and Sarah Barton with newborn son William in November 1999, the week of Expedia’s IPO. (AP / Daytona Beach News-Journal) Within two years, Expedia had surpassed Travelocity to become the largest online travel company. Barton left in 2003, eventually going on to co-found ventures including Zillow and Glassdoor, applying the same “power to the people” philosophy — giving consumers access to data that industries had previously kept behind walls — to real estate and the job market.

Before Barton left, controlling interest in Expedia had passed to a new owner. But the deal that made it happen nearly didn’t survive the worst moment in the history of modern travel.

Chapter 2: ‘If there’s life, there’s travel’ Barry Diller was a Hollywood legend who had built Fox Broadcasting and launched the Home Shopping Network when he turned his attention to the internet in the late 1990s. 

Through his company, USA Networks, he was assembling a portfolio of online brands, and he saw travel as the biggest opportunity. Travel, he wrote in his 2025 memoir, Who Knew, looked like “the perfect business to be colonized by the internet.” He had already acquired Hotels.com when he approached Microsoft about buying its controlling stake in Expedia. 

Expedia Group’s then-Vice Chairman Peter Kern, Chairman Barry Diller, and future Expedia Group CEO Ariane Gorin, then president of Expedia Business Services, on stage at a company Town Hall meeting in December 2019. (Expedia Photo) Expedia was still losing money, and Ballmer had concluded that Microsoft shouldn’t be in internet verticals anyway, as Diller recalled in the book. With relatively little negotiation, Microsoft agreed to a deal worth about $1 billion in USA Networks stock.

They were set to close the deal in October 2001. Then, on September 11, the travel industry shut down in an instant. The deal included a material adverse change clause — a legal escape hatch that would have let Diller walk away. For weeks, his team debated whether to use it. 

How could they pay $1 billion for a travel company when no one was traveling?

“Some people said, you shouldn’t do it, it’s too dicey, there’s no travel, the world is ending,” Diller told GeekWire in 2016, on the company’s 20th anniversary.

But then, someone in the room said, “If there’s life, there’s travel.”

“Yeah, that’s what we’ll do,” Diller recalled saying. “We’ll bet on life.”

The next transition The deal closed in February 2002. Diller folded Expedia into a division of his company called IAC Travel. When the head of that division resigned, a young executive named Dara Khosrowshahi raised his hand. Khosrowshahi had first crossed paths with Diller as a junior analyst at the investment bank Allen & Company, and had been in the room during the 9/11 deliberations. 

“Barry was desperate. He had no one else,” Khosrowshahi recalled on the Diary of a CEO podcast. 

In 2005, Diller spun IAC Travel back out as a standalone public company — Expedia, Inc. — with Khosrowshahi as CEO. He moved to what he later called “the Netherlands of Seattle.” He would hold the role for 12 years, longer than any leader in the company’s history.

It was under Khosrowshahi that Expedia navigated the shift from desktop to mobile. As travelers migrated to smartphones, the company rebuilt its products for the small screen.

Khosrowshahi also led an acquisition spree that transformed Expedia from a single brand into a travel conglomerate, adding Orbitz, Travelocity, Trivago, and others along the way. 

Competition from all corners Even as Expedia consolidated its position in online travel, a different kind of threat was emerging. Google was pushing into travel directly through Google Flights and Google Hotels, and its search algorithm had become the dominant gateway to travel shoppers — making the search giant Expedia’s biggest advertising channel and one of its largest competitors.

Google’s position is “a reality of e-commerce,” Khosrowshahi said in a 2016 interview with GeekWire, on the company’s 20th anniversary, in the conference room at its Bellevue, Wash., headquarters. “It’s reality of the Internet, and it’s certainly a reality of this category in general. That’s not going to stop.

Then-Expedia Group CEO Dara Khosrowshahi at the company’s Bellevue HQ in 2016. (GeekWire File Photo / Kevin Lisota) The bigger direct threat, though, was emerging from across the Atlantic. The Priceline Group — later renamed Booking Holdings — had acquired Booking.com out of Amsterdam in 2005, building a business that would eventually surpass Expedia in gross bookings.

“Priceline is our toughest competitor,” Khosrowshahi said at the time, calling it a great company that had quickly expanded its international reach. “They’re more global than we are.”

And then there was a competitive threat that nobody at Expedia had anticipated: the rise of vacation rentals as a category, led by Airbnb. Expedia’s response was its biggest deal yet: the 2015 acquisition of HomeAway, which would later be rebranded as Vrbo — a $3.9 billion bet on the category.

“I think the growth of Airbnb has been pretty extraordinary, and I think anyone who would say today, ‘Oh, we expected it,’ would be lying,” Khosrowshahi said in the interview. 

The one exception, he acknowledged, was Airbnb founder Brian Chesky, who was known for transforming the world of lodging just as Uber’s Travis Kalanick had upended transportation.

‘You’re f’ng crazy’  The next year, Uber came calling for Dara. 

At the time, the ride-hailing company was in turmoil — embroiled in scandals, burning billions, and in need of a leader who could steady the ship. When Khosrowshahi told Diller he’d been offered the job as Uber’s CEO, the chairman’s first reaction was to hang up on him.

“He’s like, you’re f’ng crazy,” Khosrowshahi said on the Acquired podcast. 

But Diller called back the next day. “Speaking as the chairman of Expedia, it will be a real mistake,” Khosrowshahi recalled him saying. “But speaking as a friend, I understand why you’re interested. How can I help?” Diller then helped him prepare his presentation for the Uber board.

In a farewell email to Expedia staff, obtained by GeekWire at the time, Khosrowshahi called Diller “the toughest, smartest, most demanding, and most human boss I’ve ever had.” 

Ketchup and mustard One of the company’s rising executives at the time was Ariane Gorin. A Berkeley, Calif., native who grew up in a French-American family, she had moved to France in 2001 and lived in Europe for more than two decades, eventually becoming a dual French-American citizen. 

The future Expedia CEO had joined the company in 2013, and her first encounter with Expedia’s leadership set the tone: she met Khosrowshahi and CFO Mark Okerstrom on Halloween, when they were dressed as ketchup and mustard. “This is the best company,” she recalls thinking.

Expedia chairman Barry Diller, center, speaks with then Expedia CEO Dara Khosrowshahi, right, and CFO Mark Okerstrom at an event marking the company’s 20th anniversary in Bellevue in 2016. (GeekWire File Photo / Todd Bishop) Okerstrom succeeded Khosrowshahi as CEO in August 2017. By comparison, his tenure was brief, most notable for Expedia’s move from downtown Bellevue to a picturesque former biotech campus on the Seattle waterfront, and an ambitious effort to unify its technology across its growing collection of brands.

After a strategy disagreement with the board over the pace and direction of the tech revamp, Okerstrom and CFO Alan Pickerill both resigned on the same day: Dec. 4, 2019. Diller, as chairman, asserted direct operational control alongside vice chairman Peter Kern, a longtime Expedia board member. 

‘I’m on the edge of revolt’ Eight days later, on December 12, 2019, Diller put his frustration with Google in writing. In an email to Google’s chief business officer, Philipp Schindler — which later surfaced in the U.S. government’s antitrust case against Google — the chairman wrote that “much of Expedia’s trouble is due to an increasingly aggressive Google.” 

Diller cited Vrbo’s payments to Google, which had risen from $21 million in 2015 to nearly $300 million in 2019, even as the traffic Google sent to VRBO stayed roughly flat.

“Google has systematically moved every lever in its hegemony over search to disembowel our businesses,” Diller wrote, describing himself as “on the edge of revolt.”

It wouldn’t be the last time Expedia found itself subject to forces beyond its control.

‘Buy the thing’ In the meantime, Diller had been shaping the company’s new home. In the mid-2010s, he had pushed Expedia to acquire a 40-acre site on Elliott Bay, formerly occupied by Immunex, maker of the arthritis drug Enbrel. The site was vacated after Amgen bought the Seattle biotech.

“Once I saw it, I just said, ‘buy the thing,’” Diller said at a 2023 company event. He wanted a campus that felt horizontal, not vertical, with what he called “a lot of ability to breathe.” 

Expedia Group’s Seattle waterfront campus. Barry Diller personally shaped details of the design. (GeekWire Photo / Todd Bishop) Over five years of planning, Diller personally shaped details down to the geometric paving stones that radiate outward from the main building like airport runways. The campus included 1,000 trees, an on-site soccer pitch, and a meeting pavilion called “the Prow,” designed to rise out of the landscape like the bow of a ship. 

Beyond the property line, Expedia funded improvements to a portion of the Elliott Bay Trail running alongside the campus. That gave the company a sense for how it could invest in outdoor public spaces — an early version of the work it’s now expanding nationwide. 

The first of Expedia’s employees began moving into the campus in October 2019. By February 2020, the move was complete, at a final cost of more than $1.1 billion. 

‘Travel finds a way’ In April 2020, when Kern was formally named CEO, COVID-19 had brought the industry to a halt. He used the moment to complete the overhaul of Expedia’s technology platform, unifying the patchwork of systems that had accumulated through years of acquisitions. 

“Travel finds a way,” Kern said in a virtual appearance at the 2020 GeekWire Summit, predicting that cities would come “roaring back,” and the industry would ultimately rebound. 

Peter Kern, then Expedia Group’s CEO, speaking at the company’s 2023 partner conference. (GeekWire File Photo / Todd Bishop) In the meantime, Gorin had been building what would become one of Expedia Group’s most important business lines. In 2014, Khosrowshahi had asked if she was interested in running the company’s affiliate network, which licensed the company’s travel technology and inventory to outside partners, letting them offer Expedia-powered bookings under their own brands. 

It was less than 10% of the company’s business, and nobody else wanted the job.

“B2B was not seen as a sexy part of the company,” she recalled recently.

Gorin jumped in with passport in hand. She spent her initial months in the job talking to partners around the world, developing a strategy of going where Expedia’s own consumer brands couldn’t or didn’t go, including offline retail, corporate travel, emerging markets, and anywhere else there were untapped pools of travel demand. 

Over the next decade, she grew the B2B division from a small afterthought into one of the company’s most important businesses. Today it accounts for roughly a third of Expedia’s overall business, powering travel programs for companies like Marriott, Hilton, United, Delta, and Capital One. 

It was, in retrospect, perfect preparation for what would come next. 

Chapter 3: ‘The agent that roams with you’  Long before ChatGPT became a household name, the head of OpenAI was already sitting on Expedia’s board. Sam Altman joined Expedia Group’s board of directors in 2019, recruited at a time when his AI research lab was still better known in Silicon Valley than in living rooms. 

In November 2022, weeks before ChatGPT was unveiled to the world, Altman appeared on stage with Diller at a private executive event for IAC, the parent media company in Diller’s portfolio. Altman demonstrated what was coming by typing a prompt asking ChatGPT about Diller’s relationship with his wife, the fashion designer Diane von Furstenberg.

What the AI produced was “extremely creative” and “somewhat salacious,” Diller recalled at Expedia’s 2023 partner conference. “Because we do have a history.” 

More than that, it was a glimpse of the future. Diller said the preview gave Expedia an early jump on generative AI. The company was one of the first travel firms to integrate ChatGPT — both as a plugin on OpenAI’s platform and as a travel-planning assistant in its own app. 

It actually wasn’t a surprise to Diller. Speaking with GeekWire back in 2016, Mr. Diller (as we were advised to call him) had described AI as “another form of magic.” Asked whether it would influence travel, he said at the time: “Of course it will. It will influence everything.” 

Altman left the board in June 2023, as OpenAI consumed his full attention.

From B2B to B2A  When Kern stepped down in May 2024, Ariane Gorin — the executive who had been steadily expanding the company’s business-to-business reach — became Expedia Group’s CEO.

She soon had a phrase for what the AI era would require: B2A, for business to agent. But there’s a risk in this new world: a human traveler might choose Expedia out of loyalty, or brand recognition, but an AI agent making the same decision might not care about any of that.

Expedia Group CEO Ariane Gorin at the company’s Explore partner conference last year. (Expedia Group Photo) In a recent interview at Expedia headquarters, Gorin said the company now has teams looking at what it means to market to machines: how to make sure an AI agent understands that an Expedia Gold member gets a VIP perk at a particular hotel, or that a traveler has One Key points to apply toward a trip.

Expedia has been building AI into its own products for years now. But more recently, it has been looking outward: embedding its service inside ChatGPT, Claude, and Amazon’s Alexa+, buying ads inside AI chatbots, and signing a deal to power Uber’s hotel bookings. (Khosrowshahi, who remains on the Expedia Group board, recused himself from the negotiations over that partnership.)

“I think that’s the future,” Gorin said. “It’s the agent that really roams with you.”

A competitive moat It’s still early. AI-native platforms like ChatGPT account for less than 1.5% of Expedia’s overall traffic, Gorin said. But the company said on its recent earnings call that getting its brands to show up in AI responses has become its fastest-growing marketing channel.

As demonstrated by Diller’s past frustrations with Google, these external dependencies can be a double-edged sword. But there are early signs that Expedia won’t be cut out of the picture. In March, OpenAI scaled back plans to let users book travel directly inside ChatGPT. 

Gorin said she wasn’t surprised, given the complexities of travel. “Trust me, it’s pretty complicated to be able to go from shopping to booking to servicing,” she said. Expedia handles 250 million customer service interactions a year, across more than 30 languages. 

“I see them as partners,” more than competitive threats, she said of the major AI platforms. “I see them as an opportunity for us to attract new travelers into our ecosystem.” 

Illustrating the ongoing importance of industry partnerships, Expedia struck a deal this spring to power hotel bookings inside the Uber app, with Vrbo vacation rentals coming later this year. Khosrowshahi, who still sits on Expedia’s board, recused himself from the deal.

Growth and challenges The company that began in 1996 as a small team inside Microsoft is now on a different scale entirely. When Expedia went public in November 1999, it had fewer than 150 employees, about $700 million in gross bookings, and a presence in four countries. 

Fast forward nearly 30 years, to the end of 2025, and Expedia had roughly 16,000 employees across nearly 50 countries, $119.6 billion in gross bookings, and a marketplace of 3.6 million lodging properties, including 2.4 million vacation rentals.

The company’s evolution has also brought challenges, including executive turnover and job cuts — with the latest round impacting 162 tech positions at the company’s headquarters earlier this year.

‘More travel equals more memories’ Gorin, meanwhile, has been putting her own stamp on the company. 

To mark its 30th year, Expedia is launching the Expedia Trails Fund, a philanthropic initiative to restore outdoor trails and protect natural landscapes across the United States. 

The initial $4.3 million will go to 11 projects, spanning destinations from Yellowstone’s Paradise Valley to Hawaii’s Kealakekua Bay, covering areas that draw more than 1 million visits annually. Expedia is partnering with The Conservation Fund, The Nature Conservancy, and Trust for Public Land, and with AllTrails to match support for the hiking app’s stewards fund. 

The effort reflects growing demand among travelers for outdoor experiences, particularly among younger generations. Gorin said the company’s earlier trail work alongside its Seattle campus helped to show what could be possible at a larger scale.

“If our trails fund really works the way we want it to, the impact we’re going to have on trails across the U.S. and elsewhere is going to be huge,” she said.

For Gorin, the initiative connects to something deeper. A few years after she joined Expedia, her sister was diagnosed with stage four lung cancer. Before she died, she offered Gorin a piece of advice: travel more, because more travel equals more memories.

“And then she said, ‘Oh, wait a minute. You work in travel. One day, you should use that story on stage,'” Gorin recalled. She told it at her first town hall as CEO.

“We are in the business of helping people make memories,” Gorin said. The common thread among all of Expedia’s CEOs over the years, she said, is a belief in the benefits of travel for people and the world, and in the potential of technology to achieve it.

‘Original vision … fully realized’ But if Expedia’s founding vision was to remove the barriers to travel, isn’t there a risk of people losing control when AI puts a new intermediary into the process? Barton, the person who started it all, doesn’t buy that. He draws a direct line from the original idea to the present moment.

“Round one was radical transparency,” he said. “We blew the doors open and gave everyone access to information that used to live only in a computer on the desk of a professional.”

AI agents, Barton asserts, are “the next unlock.” Rather than replacing the human in the loop, he said, they give every traveler “the equivalent of a brilliant, tireless expert in their corner.” That makes AI an accelerant for the concept of “Power to the People,” not a replacement.

“I don’t see it as a threat. I see it as the original vision, finally fully realized,” he said. “We started by turning the screen around. Now we’re handing people the whole toolkit.”
2026-06-12 19:37 3mo ago
2026-05-19 18:55 3mo ago
Expedia Group Unveils New AI Experiences, Expands Travel Ecosystem and Launches Philanthropy Program at Explore 2026
EXPE Expedia
FMP Stock News
Original source text
LAS VEGAS--(BUSINESS WIRE)--Thirty years after bringing travel online — and into reach for millions of people — Expedia Group is taking its next visionary steps for the future of travel: unveiling new AI-powered traveler experiences, marketplace capabilities and a long-term philanthropic commitment to protect the places people love to visit. At Explore 26, its annual partner conference, the company's founding and defining leaders — Rich Barton, Dara Khosrowshahi, Barry Diller, and current CEO A.
2026-06-12 19:37 3mo ago
2026-05-20 09:00 3mo ago
Expedia Group B2B Introduces AI Toolkit and Platform for the Future of Travel Distribution
EXPE Expedia
FMP Stock News
Original source text
New AI capabilities, expanded ground mobility, and merchandising capabilities help brands add and scale end-to-end travel experiences

LAS VEGAS--(BUSINESS WIRE)--Expedia Group B2B today announced a new set of AI-powered products and partnerships that make it easier for companies in any sector to build travel into their customer experiences.

“For decades we’ve built the plumbing behind the scenes that makes travel work more connected, seamless, and trusted, bringing together supply, pricing, payments, service and more,” said Alfonso Paredes, President B2B & Chief Commercial Officer Expedia Group. “Now we’re making that infrastructure even easier for partners to plug into. With one connection, partners can build more complete travel experiences for their customers, capture more of the trip, and do it with less complexity.”

Expedia Group B2B today serves 75,000 partners across industry verticals and 200,000 travel advisors, and its platform processes 21 billion API calls a day (Expedia Group internal data, 2025).

AI toolkit for partners + new travel platform

At the Explore 26 partner conference, Expedia Group B2B previewed its new, in-development AI toolkit, which rolls out with select partners in the coming months. It simplifies how B2B partners connect Expedia Group capabilities into AI experiences across APIs, interfaces, and agent workflows.

At the core is the Intelligent Experience Platform, a set of composable AI components designed to help partners launch branded travel experiences powered by Expedia Group intelligence. Expedia Group B2B aims to reduce the time and investment required for partners to launch travel experiences and help them prepare for a future where travelers increasingly expect AI-assisted trip planning.

Expanding ground mobility to complete more trips

To help partners capture more of the end-to-end journey, Expedia Group B2B is expanding its car rental, ground transport and Insurtech solutions.

In a separate announcement today, Expedia Group shared it has entered into an agreement to acquire CarTrawler, an Ireland-based B2B platform powering leading travel brands.

CarTrawler follows Expedia Group’s recent acquisition of Tiqets, the Amsterdam-based activities and experiences platform, and together the acquisitions advance the growth strategy the company outlined to expand its Rapid API beyond lodging to include car, flights, activities and trip protection.

CarTrawler’s capabilities, coupled with Expedia Group’s extensive scale, technology and partner network, unlock several new growth opportunities for partners as well as unrivaled choice and value for travelers. The transaction, which remains subject to customary closing conditions, is expected to close in the second half of 2026.

Marketing and media capabilities to reach more travelers

At Explore ‘26, Expedia Group also announced marketing and media network enhancements that help partners reach more travelers in more places.

For Rapid API partners, two new merchandising solutions can help drive demand and improve conversion:

The B2B Partner Portal account can now be used to plan and track marketing strategies. The new Merchandising API can now be tapped to build compelling marketing experiences across platforms and channels. Expedia Group Advertising also shared advances to its Travel Media Network, including:

An enhanced AI-powered advertising portal, with strategies like Max Room Nights bidding. Richer ad formats across search results, property pages, Trips, and checkout. Broader reach via DSPs and exclusive media partnerships. Trust and support built in

Across these launches, Expedia Group emphasized the governance and infrastructure behind its B2B platform:

A Responsible AI Council that reviews high-risk AI deployments before they scale. Servicing remains a core strategic priority, with continued investment in people, processes, and AI as the B2B network grows. Expedia Group B2B currently: Handles more than 7 million servicing calls a year for partners. Provides 24/7 native voice support across 25 languages. “Partners want growth, but they also want to know their brand and their customers are in safe hands,” Paredes said. “A year ago, we said we would build a broader platform for partners, and we did. Today, we’re helping partners sell more, serve better, and capture more of the trip, using infrastructure that’s been tested at scale for decades.”

About Expedia Group

Expedia Group, Inc. (NASDAQ: EXPE) is the global travel marketplace with one purpose: to help travelers explore the world, one journey at a time. Expedia Group™ connects travelers, partners, and advertisers through its trusted brands, leading technology, and rich first-party data, delivering predictive, personalized experiences that shape the future of travel.

Expedia Group’s ecosystem includes three flagship consumer brands – Expedia®, Hotels.com®, and Vrbo® – the largest B2B travel business, and a premier advertising network. Guided by an experienced and passionate global team, Expedia Group helps millions of travelers in more than 70 countries explore the world with confidence and ease.

© 2026 Expedia, Inc., an Expedia Group company. All rights reserved. Expedia Group and the Expedia Group logo are trademarks of Expedia, Inc. CST: 2029030-50.

For more information, visit www.expediagroup.com.
Follow Expedia Group on Facebook, Instagram, X and LinkedIn.
Follow Expedia on Facebook, Instagram, TikTok, Pinterest, X and YouTube.
Follow Vrbo on Facebook, Instagram, TikTok, Pinterest, and X.
Follow Hotels.com on Instagram, TikTok, Facebook and X.

More News From Expedia Group, Inc.
2026-06-12 19:37 3mo ago
2026-05-20 09:00 3mo ago
Expedia Group announces agreement to acquire CarTrawler, advancing strategy to build the most complete B2B travel platform
EXPE Expedia
FMP Stock News
Original source text
Acquisition enhances Expedia Group’s ability to deliver mobility and Insurtech solutions for travelers worldwide through its B2B platform and consumer brands

SEATTLE--(BUSINESS WIRE)--Expedia Group today announced that it has entered into an agreement to acquire CarTrawler, an Ireland-based B2B platform powering car rental, ground transport and Insurtech solutions for the global travel industry.

CarTrawler’s platform brings exceptional depth, breadth and expertise across these areas, connecting 550+ car rental suppliers and 500+ mobility suppliers to more than 300 leading travel brands around the world, including more than 70 airlines.

CarTrawler’s capabilities, coupled with Expedia Group’s extensive scale, technology and partner network, unlocks several new growth opportunities. Supply partners get access to incremental demand through a much larger distribution base. B2B demand partners get richer, more comprehensive access to car rental, ground transport and Insurtech supply at highly competitive rates as well as customized technology for seamlessly integrating these solutions into their existing platforms. Travelers in turn get unrivaled choice and superior value, whether booking through Expedia Group brands or via B2B partners.

“The CarTrawler acquisition is another huge, exciting step towards our ambition of building the most complete B2B travel platform,” said Alfonso Paredes, President B2B & Chief Commercial Officer, Expedia Group. “Last year, Expedia Group B2B set out a bold vision to expand our APIs beyond lodging. Acquiring Tiqets helped us solve for activities at scale. Adding CarTrawler now extends that same strategy into car rentals, ground transport and Insurtech. CarTrawler’s focus and differentiated expertise in these areas complements our strengths in B2B scale and technology, enabling us to massively amplify our joint value proposition to partners, suppliers, and travelers.”

“CarTrawler’s acquisition by Expedia Group is a testament to the strength of our technology, the drive of our people, our track record of innovation, and our accelerating commercial momentum,” said Peter O’Donovan, CEO of CarTrawler. “This exciting combination allows us to advance our mission as part of travel’s best and most complete B2B engine, unlocking new opportunities for innovation and growth.”

The transaction, which remains subject to customary closing conditions, is expected to close in the second half of 2026.

About Expedia Group

Expedia Group, Inc. (NASDAQ: EXPE) is the global travel marketplace with one purpose: to help travelers explore the world, one journey at a time. Expedia Group™ connects travelers, partners, and advertisers through its trusted brands, leading technology, and rich first-party data, delivering predictive, personalized experiences that shape the future of travel.

Expedia Group’s ecosystem includes three flagship consumer brands – Expedia®, Hotels.com®, and Vrbo® – the largest B2B travel business, and a premier advertising network. Guided by an experienced and passionate global team, Expedia Group helps millions of travelers in more than 70 countries explore the world with confidence and ease.

© 2026 Expedia, Inc., an Expedia Group company. All rights reserved. Expedia Group and the Expedia Group logo are trademarks of Expedia, Inc. CST: 2029030-50.

For more information, visit www.expediagroup.com.

Follow Expedia Group on Facebook, Instagram, X and LinkedIn.

Follow Expedia on Facebook, Instagram, TikTok, Pinterest, X and YouTube.

Follow Vrbo on Facebook, Instagram, TikTok, Pinterest, and X.

Follow Hotels.com on Instagram, TikTok, Facebook and X.

About CarTrawler

CarTrawler is a leading B2B technology platform powering car rental, ground transport and insurtech solutions for the global travel industry. Through its proprietary Connect Platform, CarTrawler enables airlines, online travel agencies and travel providers to unlock high-margin ancillary revenue and deliver seamless end-to-end customer experiences.

Trusted by many of the world’s leading travel brands, including Ryanair, American Airlines, Air France-KLM, Uber, easyJet, eDreams ODIGEO and American Express, CarTrawler connects partners to a global network spanning over 50,000 locations.

Headquartered in Dublin, with offices in Paris, London, New York and Sydney, CarTrawler’s team of over 300 specialists combines deep industry expertise with advanced technology to drive partner success at scale. Its platform leverages data science, machine learning and dynamic pricing to optimise performance, increase conversion and maximise revenue.

Forward Looking Statements

All statements in this press release, other than statements of historical fact, are forward-looking statements, including, without limitation, statements regarding the anticipated benefits and timing of the proposed transaction. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Expedia Group assumes no obligation to update any forward-looking statements as a result of new information, future events, or otherwise.

More News From Expedia Group, Inc.
2026-06-12 19:37 3mo ago
2026-05-20 09:10 3mo ago
Expedia Group, Inc. (EXPE) Discusses Evolution of Travel, Industry Resilience and Future Innovation Transcript
EXPE Expedia
FMP Stock News
Original source text
Expedia Group, Inc. (EXPE) Discusses Evolution of Travel, Industry Resilience and Future Innovation Transcript
2026-06-12 19:37 3mo ago
2026-05-20 15:54 3mo ago
Expedia Boosts B2B Travel Offering With CarTrawler Acquisition
EXPE Expedia
FMP Stock News
Original source text
Expedia is acquiring CarTrawler, an Ireland-based B2B platform for the travel industry. “The CarTrawler acquisition is another huge, exciting step towards our ambition of building the most complete B2B travel platform,” Alfonso Paredes, Expedia's president for B2B and chief commercial officer, said in a news release Wednesday (May 20).